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The incidence of breast cancer related lymphedema (BCRL) is estimated to be at 30% for 
women who undergo breast cancer treatment, thus creating the need for effective treatment 
interventions. This thesis will compare the immediate and short-term effects of three different 
interventions for BCRL (e.g., Manual Lymphatic Drainage (MLD), Aqua Lymphatic Therapy 
(ALT), and a Casley-Smith based exercise routine (CSER)) and to record any changes in 
physical symptoms after each intervention. Sixteen women between the ages of 35 and 75 with 
Stage II lymphedema were recruited. Each intervention was completed once by each participant 
and lasted approximately 45 minutes. Bilateral limb measurements to estimate changes in 
volume were performed using bio-impedance spectroscopy and circumferential arm measures. 
The Lymphedema Breast Cancer Questionnaire was utilized to subjectively gauge any change 
in symptoms. The main findings were: ALT was the only intervention that showed a significant 
(p≤0.05) decrease in extracellular fluid (ECF) from baseline to 20-24hrs post-intervention. When 
compared to the MLD, the ALT intervention demonstrated a 3.31% greater (p=0.038) reduction 
in ECF volume over 24hrs. With respect to circumferential arm measurements, there was a 
significant difference (p=0.021) in the percentage change between ALT and MLD at 10 min post 
intervention. No other circumferential arm measurement differences exist between ALT vs 
CSER or MLD vs CSER. There were no changes or any worsening symptoms following any 
interventions. Conclusion: In the immediate to short-term post-intervention period, ALT appears 
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Table 1: Abbreviations 
ALT Aqua Lymphatic Therapy 
BCRL breast cancer related lymphedema 
BIS bioelectric impedance spectroscopy 
CB multi-layered compression bandaging  
CDT 
Complete (or Complex) Decongestive Therapy combination of MLD, compressive garment, 
exercise instruction and skin care 
CM circumferential arm measurements with tape measure 
CDT Complete (or Complex) Decongestive Therapy 
CS compressive sleeve 
CSER Casley-Smith based exercise routine 
ECF extracellular fluid 
HR Hazard ratio: LE edema volume increase of ≥ 50% 
LBCQ Lymphedema Breast Cancer Questionnaire 
SLD Simple lymphatic drainage (self-massage) 
SM Self-management 
SP Standard physiotherapy: bandage, elevation, head–neck, shoulder exercises and skin care 




The primary focus of this thesis is centered on the assessment and treatment of breast cancer 
related lymphedema (BCRL). The project was coordinated and all outcome measures were 
performed by the author at the McGill Nutrition and Performance Laboratory of the McGill 
University Health Center. This thesis contains the following two manuscripts: 1) “Determining 
the precision of dual energy x-ray absorptiometry and bioelectric impedance spectroscopy in the 
assessment of breast cancer-related lymphedema (accepted for publication by Lymphatic 
Research and Biology) and 2) (“A comparison of three intervention methods for women with 
breast cancer-related lymphedema: a pilot study”). 
The incidence of breast cancer-related lymphedema (BCRL) is approximately 30% for women 
who undergo breast cancer treatment (e.g. mastectomy, axillary node dissection and/or 
radiation treatment) (Williams A, 2005), (Petrek, Senie, Peters, & Rosen, 2001). BCRL is a 
condition that results in swelling of the arm(s), hand(s) and/or breast(s) initially caused by an 
accumulation of protein-rich interstitial fluid. The composition of BCRL has been shown to 
evolve from the initial accumulation of fluid to the development of more solid depositions such 
as fibrotic lesions and abnormal fat accumulation.  
Therefore, since the development of BCRL appears to evolve from a fluid to a more solid 
consistency, precise and reliable measures from an assortment of different assessment tools 
are required to develop accurate staging and management. Techniques such as dual-energy x-
ray absorptiometry (DXA) and bioelectric impedance spectroscopy (BIS) are two measurement 
devices that are gaining prominence and acceptance in the lymphedema research community 
with regards to their safety, ease of measurement and ability to estimate soft tissue and fluid 
components, respectively  (Gjorup C, 2010), (Czerniec S. A, 2010),(Paskett E.D, 2012). There 
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is little published information on the precision of these two instruments for edematous upper 
extremities, particularly when they are both derived from one cohort of women on the same day. 
This is the topic of the first manuscript within this thesis.  
Velanovich (1999) revealed that for a significant number of patients with BCRL the disorder is 
physically as well as emotionally disabling. The physical symptoms (e.g., stiffness, numbness, 
and fatigue) and functional outcomes (e.g., decreased strength and range of motion) place a 
constant and significant burden on women with BCRL that affects their quality of life  (Passik, 
1998). Although there are a growing number of different treatment interventions, little is known 
about the efficacy of these treatments in terms of either maintaining or reducing BCRL. The 
second study with two measures of limb volume as outcome measures, investigated the 
following three treatment interventions: 1) ALT, 2) MLD, and 3) CSER) over a 24 hour period. 
As an introduction to the topic the following review of literature addresses what is known about 










CHAPTER 1: REVIEW OF THE LITERATURE  
This literature review contains an overview of BCRL and an examination of three modalities 
(e.g., Manual Lymphatic Drainage, Aqua Lymphatic Therapy, and Casley-Smith based exercise 
routine) that are used to maintain or reduce limb volume associated with BCRL. Specifically, 
studies will be reviewed as a means of examining how effective these modalities are for limiting 
the progression of BCRL.  
Background  
BCRL is a chronic condition that results in swelling of the arm(s), hand(s) breast, and /or chest 
wall caused by an accumulation of protein-rich interstitial fluid. This increase in fluid is generally 
the result of surgical interventions and medical treatment for breast cancer (e.g. mastectomy, 
lumpectomy, axillary node dissection and radiation) that has damaged the lymphatic vessels of 
the axillary region inhibiting the clearing of intercellular fluid by the lymphatic system to the 
venous system  (Thomas-MacLean R, 2008). Lymph fluid consists primarily of proteins, water, 
fatty acids, salts, white blood cells (e.g. T-cells, macrophages) and microorganisms. As a result 
of the obstructions or the removal of the primary lymphatic channels, the stagnant lymph 
significantly changes the dynamics of capillary fluid exchange such that interstitial colloid 
osmotic pressure increases creating localized edema. The subsequent swelling interferes with 
the oxygenation of the tissues (PO2 and PCO2) in the surrounding area reducing healing and 






Table 2: Stages of lymphedema according to International Society of Lymphology  
*Pitting: an indentation made with a finger that persists for some time after the release of pressure 
Progression of this chronic condition (e.g. lymphatic stasis and protein-rich edema) will 
eventually lead to functional and structural changes within the dermis and subcutaneous tissue 
as evidenced by the development of fibrotic lesions and abnormal fat deposition  (Tassenoy A, 
2009). There is strong agreement among the experts in the field that in most cases BCRL is a 
chronic, incurable condition that will gradually progress without treatment  (Cornish, et al., 
2001),  (Bar Ad, et al., 2010),  (Piller & Carati, 2009). through a number of different stages. The 
progression of lymphedema is classified into four stages according to the International Society 
of Lymphology (Lymphology, 2009) (see Table 2).   
Stage 
Description of the Stages of Lymphedema 
0 
Subclinical state where swelling is not evident despite impaired lymph transport. 
This stage may exist for months or years before edema becomes evident 
I 
This represents early onset of the condition where there is accumulation of tissue fluid 
that subsides with limb elevation. The edema may be pitting* at this stage 
II 
Limb elevation alone rarely reduces 
swelling and pitting is manifest 
Late stage II: There may or may not be pitting 
as tissue fibrosis is more evident   
III 
The tissue is hard (fibrotic) and pitting is absent. Skin changes such as thickening, 
hyper pigmentation, increased skin folds, fat deposits and warty overgrowths develop  
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 Along with hand, arm and breast swelling, other physical symptoms of BCRL include arm 
tenderness, soreness, numbness, aching, pain, heaviness, fatigue, tightness, firmness, stiffness 
and recurrent infections as well as psychological, social, sexual, and functional problems  (Fu, 
2009). The appropriate treatment upon diagnosis of BCRL, as outlined in the Position Statement 
of the National Lymphedema Network, is Complex (or complete or combined) Decongestive 
Therapy (CDT), also called Complex Physical Therapy CDT consists of the following two 
phases: Phase I (limb volume reduction) is an intensive 2-6 week course of treatment with a 
lymphedema specialist that includes 4 components: 1) MLD; 2) skin care; 3) daily compression 
bandaging used to achieve a compression gradient and; 4) remedial exercises  (Network, 
2009). The two main goals of this phase are to reduce the volume of the lymphademetous limb 
and to attend to any skin irritations and to prevent infections that are common sequelae to a 
condition of impaired lymphatic function. Phase I continues until the limb volume reduction has 
reached a plateau for 2-3 days at which point the patient moves into the next phase. Phase II of 
the CDT protocol is considered to be a maintenance period. For the most part, the patients 
themselves are responsible for Phase II and will need to take self-directed measures for the rest 
of their lives to maintain the limb volume reduction. Standard practice for clinicians treating 
BCRL is to educate the patient throughout Phase I on skin care and refer to lymphedema 
therapists and remedial exercise instructors for instruction on self- massage and home-based 
exercises  (Lawenda, Mondry, & Johnstone, 2009). This is to facilitate the self management 
required in Phase II for the maintenance of the limb volume reduction. At the end of Phase I, the 
clinician fits the patient with a compressive garment to be worn on the arm according to need. 
For some, the garment needs to be worn throughout the waking hours but, others may have to 
wear the compressive garments over the entire day and night for the long term maintenance of 
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their arm volume. The other components of Phase II are: 1) continued skin care; 2) remedial 
exercises; 3) compressive bandaging; 4) MLD and; 5) self massage. 
The three treatment interventions (MLD, ALT and CSER) 
The focus of this review is MLD and two different remedial exercise routines (ALT and CSER) 
and their effectiveness in reducing and or maintaining the limb volume in BCRL. In 1936, Emil 
Vodder (Williams A. , 2010) developed and was the first to present MLD as a method of 
massage for lymphatic drainage. This method of massage incorporates gentle circular 
movements in specific directions, using an approximate pressure of 30mmHg, and rest periods 
stretching the skin and attempting to encourage lymph flow via lymphatic contractions. The 
CSER was specifically created for the treatment of upper and lower limb lymphedema (Casley-
Smith J.R, 1998). This exercise routine involves daily low-intensity exercises of 20-45 minutes 
performed in a particular sequence to theoretically augment the normal lymphatic pumping 
action of muscles (Havas E P. T., 1997). ALT is a water-based intervention that takes 
advantage of the natural hydrostatic pressure gradient of the swimming pool. The exercises 
involve the shoulder girdle, abdomen, head and neck, and then the distal arm. In addition to 
causing a massage effect, the limb position and direction of movement during exercise in the 
water encourage lymph flow away from the affected arm. 
Methods 
Search strategy:  A survey of the literature was carried out using the electronic database 
PubMed/ (Medline) entering the following keywords and phrases: manual lymphatic drainage; 
Casley-Smith exercise or aqua-therapy or immediate treatment, and breast cancer related 
lymphedema (BCRL); breast cancer and arm swelling; BCRL and maintenance. All titles were 
screened and abstracts of potentially relevant articles were analyzed. Criteria for inclusion in 
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this review were fourfold: 1) BCRL studies published within the last ten years; 2) being available 
in English through open access; 3) MLD, ALT or Casley-Smith based exercise (CSER) as one 
level of the independent variable and; 4) limb volume as one of the outcome measures.                                                                           
Review of Literature 
Though there have been no randomized clinical trials measuring the efficacy of CSER as the 
sole intervention, there was one cross-sectional study group report of eight women attending 8 
x-1 hr classes per week of CSER  (Bracha, 2010). The outcome measures of this study were 
pre- and post- limb volume and Quality of Life. The results showed that the average reduction of 
limb volume after each class was 26ml with a range of 12-44ml. After eight weeks, 5 women 
had achieved volume reduction >15% with a range of 16-88%. The remaining three women had 
maintained their pre-intervention arm volume measurements.  
With respect to ALT, four research articles were found; however, only one article satisfied the 
selection criteria. In their single-blind, randomized clinical trial, Tidhar & Katz-Leurer (2010) 
recorded the long-term effects of ALT. The treatment group participated in weekly ALT classes 
for 3 months and the control group was asked to perform self management and was given 
exercise and self-massage instruction booklets. The major findings included a significant and 
immediate post intervention reduction in limb volume; however, no significant volume reduction 
was observed at the end of the 3-month study period. Of interest, the adherence rate for the 
ALT classes (79%) was significantly greater than the self-management (<30%) over the same 
period. 
The body of knowledge on the two exercise interventions (e.g. ALT & CSER), is greatly lacking 
with only one recent publication for each (Bracha, 2010), (Tidhar D., 2010). 
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For MLD, seventeen research articles were found of which 7 studies were excluded because 
MLD was utilized for cellulite reduction (1); limb volume was not an outcome measure (2); 
studies assessing leg lymphedema (2) or non cancer treatment related limb edema (2). Ten 
studies investigating the effectiveness of MLD are presented in Table 3. In total, including the 
the studies from the other two interventions, this review includes 12 research studies with a total 
of 1592 participants.  
The comparison of the 10 MLD studies in this review is challenging due to the heterogeneity of 
the study designs. For example, the duration of interventions varies from one treatment session 
to 4 years of treatment. The comparative variables vary from counseling to self-massage to 
CDT. A similarity amongst the studies was that 8 studies utilised circumferential measures of 
limb volume as an outcome measure.  
This review identifies five studies that compare MLD with CDT (e.g. compressive bandaging, 
compressive sleeve, remedial exercise and skin care), or one or more of the CDT components.  
The results from these studies are mixed. Starting with the studies that address measurements 
after a short-term course of MLD treatment, Maher et al. (2012) combined MLD with the use of 
the compressive sleeve and compared it with MLD alone in a single session design using BIS 
and perometry to measure any volume changes at 30min intervals for two hours. No significant 
change in volume for either intervention was observed. The sample size in this study was small 
with n=15 in each group. Another weakness was having the assessments done by the MLD 
therapist that may have lead to a measurement bias.  
A randomized control trial compared standard physiotherapy (SP: bandage, elevation, head–
neck, shoulder exercises and skin care) group (n=26) to CDT group including MLD (n=27) all 
received treatment three times per week for four weeks (Didem, 2005). The findings were 
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significant with a mean volume reduction for both the SP group (36%) and the CDT group 
(55.7%). When comparing these two groups the volume reduction was significantly greater for 
the CDT group (p< 0.005). 
McNeely (2004) compared MLD & CB group (n=24) to CB group (n=21) over a 4-week period 
where the MLD group received 5 treatments per week . Significant volume reductions in the 
both groups were observed and the authors concluded that there is no significant difference in 
volume reduction with or without the use of MLD.  
Four of the ten MLD related studies were carried out over a period of 12-months or longer. Koul 
et al. (2007) assigned one group (n=76) a combined MLD & CDT intervention and compared it 
with a group (n=44) receiving MLD alone over a 12-month period. Their findings showed MLD 
alone reduced limb volume significantly yet; the reduction was 10% higher when CB and 
exercises were also part of the treatment. There were several limitations to this study including 
the fact that the participants were not randomized to the different groups and the treatment 
frequency was left up to the discretion of the individual therapists. 
Vignes et al., (2006; 2010) have reported on two, long-term prospective studies. Their initial 
study compared three components (MLD, CB, and CS) following two 6-month intervals of the 
Phase II maintenance program in 358 BCRL patients (Vignes S, 2006). Significant increases in 
limb volume were found with CB (p<0.0001) and CS (p=0.002) but not MLD and it was 
concluded that noncompliance was the key risk factor in determining this outcome after one 
year. Some of the limitations of this study include non-randomization of participants to the 
treatments, lack of a systematic method of tracking compliance to the treatments and the 
authors indicate a high proportion of participants were lost to the 12-month follow-up. The 
second and longer prospective study was conducted over a four year period with milestone 
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comparisons at 1, 2, and 4 years.  A total of 682 patients were assessed and evaluated with 
MLD, CS and the combination of interventions (e.g., MLD & CB and MLD&CS) (Vignes S., 
2009). The measurements at 12 months were used to calculate the “Hazard Ratio” (HR) (1.00 
being the ratio that identified a limb volume increase > 50% above baseline). The lowest HR 
was found with the group using CB & CS with a ratio number less than 1.00 (p=0.004); MLD 
(HR > than 1.00 p=0.03) alone was the worst. The higher ratio indicates a higher likelihood of 
increasing limb volume > 50 %. These results indicate that in the long term a maintenance 
program containing MLD alone is not of benefit to these women with BCRL. The study 
weaknesses include 1) non-randomizing of patients to treatment and 2) the self-recording of 
compliance to treatments which may contain some patient error. 
Reul-Hirche (2011) carried out a randomized controlled trial over a 12-month period with 160 
breast cancer survivors having undergone axillary lymph node dissection. The outcome 
measure was the incidence of LE. The patients were randomized to one of two groups. The first 
group (n=81) received guidelines for LE prevention and exercise training. The second group 
(n=79) received the same guidelines and exercise training and 40 sessions of MLD. The 
authors concluded that there was no additional benefit of MLD since there were no differences 
in the incidence of LE at 3, 6, or 12 months. Furthermore, the addition of MLD to guidelines for 
LE prevention and exercise training does not appear to prevent the onset of LE in the 1st year 
after surgery for axillary lymph node dissection. 
Three of the ten studies involved Simple Lymphatic Drainage (SLD), which is a layman’s 
variation on MLD involving the same sequence of movements and massage done by the 
patients on themselves following the individualized instruction by a lymphedema therapist. Two 
of the studies compared this form of self-massage (SLD) with MLD. In the first of these studies, 
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Williams et al. (2002) using a cross-over design for a 21-day intervention treatment period in 29 
patients, found a significant mean limb volume decrease of 71ml (p=0. 013) with the MLD with 
small (30mls) insignificant changes with SLD. With similar results, the second study involving 
MLD and SLD compared the percentage change in excess limb volume over a 14-day treatment 
period and found a significant decrease of 33.8% with MLD (n=15), but no significant change 
with SLD (n=13)  (Sitzia, Sobrido, & Harlow, 2002). However, neither of these studies found a 
significant difference between SLD and MLD in terms of the decreases in limb volume. Taking 
into consideration the relatively small sample sizes of these two studies, it would be premature 
to state that MLD is relatively more effective than SLD.  
Finally, a crossover study that compares self-massage with a garment, which utilizes a 
compression pump, that is purported to simulate the actions of MLD was added to the review for 
its novel perspective and its contribution to the body of knowledge on self-massage (Wilburn O, 
2006). This crossover study by Wilburn et al. (2006) involved a small group (n=10) participating 
who were randomly assigned into two, 14-day treatment periods; one with SLD and the other 
with the Flexitouch™ (mechanical pressure garment). The results of this research demonstrated 
a significant mean volume reduction of 208ml ±157ml (p=0.002) over time with the Flexitouch™ 
and a non-significant mean volume increase of 52ml ± 106ml with SLD. The post-treatment 
volume differences between the two interventions found the Flexitouch™ garment had a 
significantly greater decrease (p=0.007) in volume compared to the SLD. Although the evidence 
is compelling to select this mechanical device over SLD, from a pragmatic perspective, this 





Table 3: Selected studies describing the treatment efficacy for women with BCRL  
Author 






Studies involving CSER & ALT 
Bracha     
et al. 
(2010) 
n=8                          
Case report 
8wk once/week 1hr 
CSER  
Bilateral limb TCvol, 
CM, from the wrist to 
axilla at 5-cm 
intervals, QoL 
Only : significant* improvement 
Emotional & Social QoL 
Tidhar       
et al 
(2010)       




ALT + SM n=16         





ALT: Significant* immediate  vol  
; no significant volume reduction 
at 3mos                                                      
ALT: significantly*greater  
adherence rate than SM                                    
Studies involving MLD 






CDT n = 27            
SP n =26 
3x/wk for 4wks 
Bilateral limb water 
displacement 
volumetry &  TCvol 
CM from the wrist to 
axilla at 5-cm 
intervals, ROM 
CDT significantly*greater vol  
than SP           
Both Significant*  ROM 
Koul         






CDT n=76    
MLD only n=44  
counseling n=18 
number of Tx over 
1yr varied 
Bilateral limb TCvol, 
CM wrist to axilla at 4-
cm intervals 
Measurements: pre & 
post Tx 
Improvement                                
CDT: 55.7% *                             
MLD: 41.2% *                   
Counseling: 24%*     
Maher      
et al. 
(2012) 
n=30 MLD n=15        MLD 
+ CS n=15 One 
session 
Perometry, BIS 
interlimb ratio- pre, 
post:30min, 60min, 
120min 
No significant change for either 
McNeely    




2 groups                           
CB n=25                   
MLD/CB n=25                     
4 week treatment 
Bilateral limb water 
displacement 
volumetry &  TCvol, 
CM  from the wrist to 
axilla at 4-cm intervals  
Measurements: pre, 1, 
2, 3, & 4 weeks post tx  
 Both treatments  arm vol  
significantly*  Patients with mild 
LE had significantly* larger vol 
reduction with MLD/CB  
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ALT: Aqua Lymphatic Therapy CB: multi-layered compression bandaging; CDT: combination of MLD, compressive 
garment, exercise instruction and skin care CM: circumferential measures; CS: Compressive sleeve; CSER: Casley-
Smith exercise routine; Hazard ratio (HR): LE edema volume increase of ≥ 50%; LE:  lymphedema; MLD: Manual 
Lymphatic Drainage;  SLD: simple lymphatic drainage (self massage); SM: self management; SP (standard 
physiotherapy): bandage, elevation, head–neck, shoulder exercises and skin care; TCvol: Truncated cone volume 
calculation  
Reul-
Hirche        




survivors  RCT 
MLD & education 
n=79   
Only education 
n=81   
MLD: 40 sessions 
over 20 wks              
Water displacement, 
HRQoL 
Baseline & 1,6,9 
&12mos     
No difference in incidence of LE at 
3,6,& 12 months 
Sitzia         




MLD n=15                     
SLD n=13                                   
2 week treatment 
 Bilateral limb, TCvol, 
CM        at 2cm 
intervals         
Measurements: pre & 
post Tx 
% change in excess limb vol.                            
MLD 33.8%                              
SLD 22% 
Vignes      





All had CDT                                     
Maintenance         at 
12 months                  
MLD n=246                 
CB n=263                 
CS n=322 
TCvol,CM from the 
wrist to axilla at 5-cm 
intervals,     
Measurements:                      
pre & post CDT and                 
6 &12mo post CDT 
CDT: vol  significantly*                         
12mo Noncompliance to CB & CS 
risk factors for arm vol  
significantly*                              
12mo Noncompliance to MLD      
not a risk factor 






MLD                                                                             
CS                                   




CM wrist to axilla at 5-
cm intervals                      
Hazard ratio: 
calculation of arm 
edema vol  ≥50% 
Measured at 1,2 ,4 yrs  
   After 12mos         Hazard ratio                   
MLD:                        1.91*                                  
CS:                           0.65                                        
MLD + CS:               1.09                              
CB + CS:                  0.53*                             
MLD + CS+CB         0.73                
∴ Better without MLD 
Wilburn     







Tx                              
SLD 14day Tx 
7 day washout w/ 
garment 
Bilateral limb TCvol 
CM wrist to axilla at 4-
cm intervals         
Measurements: pre & 
post Tx  
Flexitouch™: significant* volume 
reduction 
SLD: no significant volume 
reduction 






SLD 21day Tx 
MLD 21day Tx 
42day washout w/ 
garment 
Measurements: pre & 
post each Tx  
                                          
Bilateral limb  TCvol, 
CM at 4-cm intervals 
Modified skinfold 
calipers  Ultrasound, 
QLQ C30         
MLD: vol  significantly*                 
SLD: volume  not significant 
Excess vol difference between 
MLD vs SLD  not significant               
Trunk edema & QoL no significant  
difference                                    
MLD: significant* discomfort,  
pain, heaviness, fullness 
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These findings show MLD has demonstrated effectiveness for reducing limb volume in the short 
term; however, MLD alone is not a replacement for standard care (e.g., compressive bandaging, 
garments and exercise), and it would appear from the studies in this review of literature, that 
standard care appears to be an effective modality without MLD. In conclusion, the efficacy of 
these three treatment interventions is not well established in the literature and there is a 
pressing need for more quality studies to establish a well founded base of knowledge for 
clinicians to draw from when creating treatment plans for women with BCRL. Although the 
studies mentioned gave evidence of immediate results, there has not been a comprehensive 
study that has recorded the 24-hour residual effect of all of these three treatment interventions 












CHAPTER 2: RATIONALE AND OBJECTIVES OF THE STUDY 
In Canada, 23,000 women are diagnosed with breast cancer each year (Statistics, 2012). 
Approximately 30% of those who survivor the cancer will develop BCRL as a sequelae to the 
cancer treatment. In Quebec 5,500 women are diagnosed with breast cancer each year 
(Statistics, 2012). For these women, most lymphedema treatments are not covered by the 
healthcare system and the high cost of “usual care” (e.g., MLD or compressive bandaging 
and/or compression garments) can make the treatment prohibitive for many of these patients. 
In spite of the education and advice concerning the maintenance phase of patients diagnosed 
with BCRL, some patients have had difficulty adhering to a maintenance program resulting in a 
return to the limb volume of their lymphademetous arm before the Phase I treatment  
(Johnstone, 2006). Another complication patients face in adhering to their maintenance program 
is the fact that some suffer adverse effects from wearing compressive garments such as hand 
swelling as well as skin irritation and pain from continuous rubbing and friction from the garment 
seams  (Vignes S., 2009). These factors highlight the challenges and importance of determining 
the most effective means for maintaining or reducing limb volume reduction for women with 
BCRL.  
The three interventions have shown immediate and positive improvements for BCRL over the 
short term  (Bracha, 2010), (Tidhar D., 2010), (McNeely, 2004). Whether the impact of ALT, 
MLD, and CSER bestow immediate effects that last over a 24hrs period remained to be seen. If 
our investigation revealed that any one of the 3 interventions provided a daily positive influence 
on maintaining or reducing limb volume, this might indicate a decreased need for the use of the 
compressive garments. This would lead to fewer physical, psychological and social side effects 
from reduced garment use and would provide a substantial savings in the purchase of these 
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garments for the lifelong maintenance of BCRL. Secondly, if the results of either ALT or CSER 
could provide evidence that either intervention is as effective as MLD, then patients will be able 
to make an informed choice before spending $80-$100 for a treatment for their 
lymphedematous arm. Most importantly, there exists the possibility that a specialized daily 
exercise routine or aqua-therapy could give a woman with BCRL added symptom relief and 
improved quality of life for very little cost if any. 
Clearly, further research is needed to present evidence in defining the most effective treatment 
available for limb volume reduction and maintenance for this lifelong condition. 
Research questions, hypotheses and study objectives 
Research Questions: The following questions have been proposed: 1) Of the three treatment 
interventions being studied which one is the most effective in promoting limb volume 
maintenance or reduction? 2) Will there be any new or changes in physical symptoms of the 
affected extremity following anyone of the treatment interventions? 3) Which one of the three 
interventions do the women prefer?  
Study Objectives:  1) To assess the immediate and short-term effects on ECF volume following 
a single bout of activity from three different interventions for BCRL (e.g., MLD, ALT, CSER), 2) 
To determine which of the three interventions is most effective in maintaining or reducing limb 
volume over a 24 hour period, 3) To record any changes in physical symptoms after each 
treatment and, 4) To ascertain which of the three modalities the women prefer. 
Hypotheses  
Based on the theory of the mechanisms at work with CSER and ALT and evidence that 
indicates muscle movement encourages lymph flow, we hypothesize that CSER and ALT will 
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have some efficacy in reducing the arm volume but, to what extent and duration is yet to be 
seen. 
The conflicting evidence on the efficacy of MLD leads us to hypothesize that MLD will have 
some immediate effectiveness in volume reduction but will not demonstrate any lasting effects 
at 24 hrs post-intervention  (Velanovich, 1999). 
If there are any changes in symptoms such as decrease in heaviness or aching they will 
correlate positively with volume reduction. Therefore, we hypothesize that there will be 
immediate positive changes in symptoms for all three interventions that may last 24 hrs for the 













CHAPTER 3: METHODS AND PROCEDURES 
Experimental Design 
This project was a repeated-measures crossover design that incorporated both multiple 
measures over time and 3 different levels of the independent variable. The advantages of this 
design include the need for fewer participants to increase statistical power as the participants 
acted as their own control. This condition also decreased the potential effects of natural 
variation. Specific weaknesses of this type of experimental design includes the possibility of the 
natural progression of lymphedema over the 5 weeks could be a potential threat to the internal 
validity of the design. Another disadvantage to this design could relate to the feasibility of 
participant recruitment and adherence due to the extended time commitment. For this repeated 
measures design all participants completed one 45min session for each of the three 
interventions over a five week period with a two week “washout” period in between 
interventions. An important consideration listed in the inclusion criteria for recruitment was that 
all the women recruited have Stage II lymphedema. Recruiting only participants with Stage II 
was crucial to limit the between participant variability.   
Approval for the study was obtained from the McGill University Health Center’s Research Ethics 
Board. This research was carried out in accordance with the Canadian government’s Tri-Council 
Policy Statement: Ethical Conduct for Research Involving Humans and the Helsinki Declaration 
of 1975, as revised in 2008. 
Participant recruitment: All eligible patients were invited to participate and 19 of the 35 women 
who were found to be eligible for the study were recruited consecutively at the McGill University 
Health Center (MUHC) Lymphedema Clinic.  All women who were recruited read and signed an 
informed consent document approved by the MUHC. The recruitment was difficult as is evident 
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in the 54% recruitment rate of the 35 potential patients. The adherence rate was 84%, three 
participants dropped out after receiving one intervention each. All questionnaires and informed 
consent documents were duly translated into French. 
Inclusion Exclusion Criteria 
Inclusion Criteria:  
 Women age 35-75  
 BMI ≤ 45 kg/m² 
 6 months or more post-breast cancer treatment  
 Breast cancer stages I-III in remission  
 Stage II unilateral BCRL (≥10% limb volume difference)  
 Having completed the intensive phase of CDT  
 Willing to refrain from wearing a compression garment for 24 hours prior to and following 
each intervention (for a total of 48 consecutive hours) on three occasions over a five 
week period  
 Not averse to entering a swimming pool  
Exclusion Criteria  
 Active cancer or significant chronic illness  
 Pre-existing heart condition (e.g. pacemaker, congestive heart failure, hypertension, 
peripheral artery disease)  
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 Pregnancy (>24weeks)   
 Treatment for lymphedema in the last two weeks (e.g. MLD and/or compressive 
bandaging)    
Patient demographics: During the initial visit a brief questionnaire (Appendix A) was 
administered to ascertain dates and types of treatment for breast cancer, date of BCRL onset 
and stage, which arm was affected and which was the dominant upper extremity. Any missing 
data was retrieved from the patients’ medical files of the MUHC Lymphedema Clinic with 
permission granted by the participant. For details of participant characteristics, see Table 6 
Interventions 
The following is a description of the three treatment interventions including a brief discussion of 
the postulated mechanisms of action.  
Aqua lymphatic therapy (ALT): is a gentle form of aqua therapy performed by the patient as part 
of a class or individually in a warm shallow swimming pool with a depth of 4 to 4.5 feet (1.2 to 
1.4 m) and at a water temperature of 88 to 91.5°F (31-33° C).  Women are not permitted in the 
pool if they have an active skin infection. Standing in the pool with the water at neck level the 
ALT session begins with chest breathing exercises attempting to clear the thoracic duct. The 
exercises are performed slowly, from proximal to distal, with the arm position taking advantage 
of the natural hydrostatic pressure gradient of the pool. Thus, the exercise period begins with 
the arms floating (15-20 minutes) and finishes with the arm vertically submerged in the water 
(15-20 minutes). The exercise sequence involves the shoulder girdle, abdomen, head and neck, 
and then the distal arm. Movements are used to clear the axillary lymph nodes, followed by side 
bending with hand pointing down to activate the latissimus dorsi and quadrates lumborum 
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muscles for proximal activation of lymph flow. The exercises end with dolphin type diving, arms 
extending in front for distal to proximal water massage. The limb position and direction of 
movement during the exercise encourages lymph flow away from the affected arm and causes a 
massage effect of the limb. Finally, deep breathing and self-massage or massage by a fellow 
participant are incorporated several times to augment the effects of the exercises at specific 
times during the sequence. 
The suspected mechanisms behind this treatment are threefold: incorporating water’s 
hydrostatic property to create a pressure gradient enhancing directional lymphatic flow; the 
viscosity of water providing resistance with movement for a gentle massage or; more vigorous 
movements in specific directions for strengthening and encouraging the extrinsic pumping of the 
lymphatic vessels by adjacent muscle movement. The sequence of movements is designed to 
initially encourage proximal clearing of lymph followed by distal to proximal movement of lymph.  
Theoretically, this combined movement is expected to lead to the reduction or maintenance of 
limb volume (Tidhar D., 2010). The authors also highlight the benefits of the group activity 
format and its social and self-efficacy benefits. For this study this intervention was lead by a 
lymphedema specialist with over 7 years of experience leading ALT classes. 
Manual lymphatic drainage (MLD): a method of massage for lymphatic drainage was developed 
and first presented at a conference in 1936 by Emil Vodder (Williams A. , 2010). This method of 
massage stretches the skin and incorporates gentle rhythmic circular movements in specific 
directions, interspersed with rest periods, using an approximate pressure of 30mmHg which 
varies according to the edema (e.g., increased pressure for breakdown of fibrotic tissue). The 
suspected mechanism to encourage lymph flow with this technique is threefold: 1) moving the 
lymph with slowly increasing pressure; 2) an attempt to create pumping by the rhythmic 
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pressure, rest (no pressure) movements; and 3) an attempt to stimulate lymphatic vessel 
contraction with the stretching of the skin. The stroking technique used in MLD is proposed to 
act as an analgesic. This is based on the neurophysiology theory that the stimulation of the 
unmylinated tactile afferents, by stroking the skin, has been shown to inhibit nociceptive 
signaling (Olausson H., 2010). The massage treatment begins proximally at the root of the limb 
and then moves in a distal to proximal direction. The massage finishes by moving from the axilla 
progressively distal. Often the thorax and the opposing limb are treated as well. A single 
treatment lasts approximately 45 minutes (Kasseroller, 1998). The MLD therapist that treated all 
the participants for this research had over 4 years of experience and had been recently 
recertified by the Dr. Vodder School. 
Casley-Smith exercise routine (CSER): is a gentle (low intensity) 45 minute exercise routine that 
incorporates breathing, slow rhythmic mild isotonic muscle contractions of the affected arm 
muscle interspersed with self-massage to promote regional lymphatic fluid movement and 
venous outflow (Casley-Smith J.R, 1998). The routine begins with deep breathing to facilitate 
clearing of the thoracic duct and proximal muscle group exercises; followed by distal muscle 
group and concluding with proximal muscle group exercises. The session ends with a period of 
relaxation. The proposed mechanism for this method involves the systematic application of 
varying pressures through movements to specific areas with the intent to create a pressure 
gradient to encourage the directional flow through the lymphatic pathways. The muscle 
contractions are believed to facilitate extrinsic pumping of the lymph through the vessels. For 
example, clearing of the thoracic duct is thought to be accomplished using deep breathing with 
synchronized chin curls and flexion/extension of the upper spine. Thus, applying varying 
pressures to the thoracic area, utilizing extrinsic pumping actions of the lymphatic vessels 
encourages the clearing of lymph from the thoracic duct into the great veins. Beginning the 
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routine proximally (with lymphatic trunks and nodes) is performed with the intent to overcome 
the hydraulic resistance in the nodes that is thought to slow post-nodal lymph flow  (Havas E P. 
T., 1997). The exercise trainer leading this intervention during this study had been trained by 
Judith Casley-Smith the developer of this exercise routine.  
To minimize a possible sequencing effect participants were assigned to receive the 
interventions (A=ALT, B=MLD, C=CSER) in one of the following five different sequences:  
A in period 1, B in period 2, C in period 3 (one participant), 
A in period 1, C in period 2, B in period 3 (three participants), 
B in period 1, A in period 2, C in period 3 (six participants), 
C in period 1, A in period 2, B in period 3 (two participants), 
C in period 1, B in period 2, A in period 3 (four participants), 
There was a “washout” period or delay between each intervention of a minimum of 10 days.  
Outcome Measures 
The pre-intervention symptom questionnaire was administered and bilateral limb volume 
measurements were taken immediately prior to receiving each intervention. The post-
intervention assessments were done at 10min, 60min and 20-24 hrs. Questionnaires: The 
Lymphedema Breast Cancer Questionnaire (Appendix B) was given before the first treatment 
intervention and an abridged version for self-reporting of symptoms (e.g., heaviness, tightness, 
numbness, and aching) was given immediately prior to the other two interventions. After the 
final intervention a structured three-question questionnaire (Appendix C) on intervention 
preference was administered. 
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Anthropometry: Body weight was measured to the nearest 0.1 kg using a digital scale (Amcells 
TBS Series, USA). Height was measured without shoes to the nearest 0.5cm using a 
mechanical stadiometer (Seca). Body mass index (BMI) was calculated as weight (kg) divided 
by height (m) squared (kg/m²).  
Bilateral changes in limb volume were measured using two methods:  
1) Bioelectrical impedance spectroscopy (BIS). Participants were in a supine position on a non-
conductive table with their arms extend slightly abducted, palms down, and with legs slightly 
apart. The skin was wiped with an alcohol swab and allowed to dry. Four electrodes were 
applied to the skin in the following locations: a current source electrode on the dorsal surface of 
the third metacarpal of the measured arm, and current sink on the third metatarsal of the foot of 
the measured side. Voltage sensing electrodes were placed on the dorsum of both wrists. With 
four leads attached to the electrodes, a small constant AC current (200μA) was passed from 
hand to foot and the drop in voltage was measured. The measures of impedance (opposition to 
the flow) of the electric current through the body fluids are used to calculate the volume of 
extracellular and intracellular fluid (Ward, Czerniec, & Kilbreath, 2009). BIS has accurately 
detected early stage lymphedema and has been used to monitor treatment efficacy (Cornish, et 
al., 2001). Most recently, BIS device used in this study has been shown to be a highly precise 
instrument and sensitive enough to detect as low as a 44ml change in ECF within the 
lymphedematous arm (Newman A, 2013). The BIS system used in this protocol was the 
ImpediMed SFB7. For the analysis, the system’s software (Bioimp version 2.25, ImpediMed 
Ltd., Brisbane, Australia) was used with the parameters set as follows: a data rejection level of 
“none” (default setting) and an operator-chosen frequency range of 3 kHz-500 kHz.  These have 
been determined to be the most appropriate settings for this population (Newman A, 2013). 
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2) Circumferential arm measures (CM). Using a standard tape measure, circumferential 
measures from the wrist to axilla at 10-cm intervals were obtained. Arm volumes were 
calculated determined by summing segment volumes derived from the truncated cone formula. 
CM is a commonly used clinical method for monitoring limb volume in the treatment of 
lymphedema and has been found to be highly reliable and correlates well with water 
displacement which is the currently accepted “gold standard” for limb volume measurement  
(Gjorup C, 2010), (Czerniec S. A, 2010), (Karges, 2003). The unaffected limb served as an 
internal control. Bilateral measurements were taken before each intervention and at 10 min, 
60min and 20-24 hours post-intervention by the author who was blinded to previous 
measurements by using a new data collection sheet for each set of measures. The author 
administered all questionnaires. The author had had three years of experience as a research 
assistant performing assessments with the aforementioned measurement tools. 
Statistical Analysis 
The statistical package used was NCSS Statistical Software (version 7.1.17; Kaysville, Utah). 
The analysis done was a 3 (interventions) x 4 (time periods) repeated measures analysis to 
estimate the variance among the volume measurements for each of the three treatment 
interventions. A p ≤ 0.05 was used to determine if the variance estimate was considered to be 
statistically significant. When a p-value of ≤ 0.05 was obtained, the Tukey-Kramer Multiple-
Comparison post-hoc test was run to determine significant differences between individual 
means. The quantitative analysis of the LBCQ questionnaires was performed using a χ2 (Chi 
squared) test. For qualitative analysis we intend to perform a structured questionnaire content 
analysis with answers grouped by themes. 
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CHAPTER 4: RESULTS AND DISCUSSION 
Results 
Within group differences: There were no significant changes from baseline ECF at any of the 
measured time points (10 min, 60min, 24 hrs) following MLD or CSER. Of the three 
interventions, only ALT had a statistically significant (p≤ 0.05) change from baseline in ECF 
volume (26.9mls) at the 24-hour post-intervention measurement period (Table 7).  
Between group differences: In comparing the ALT vs MLD interventions from baseline to 20-
24hrs, ALT has a 3.3% greater (p=0.038) mean percentage ECF volume change than MLD at 
20-24 hours (Table 8). No other ECF differences exist between ALT vs CSER or MLD vs CSER. 
With respect to circumferential arm measurements, there was a significant difference (p=0.021) 
in the percentage change between ALT and MLD at 10 min post intervention. No other 
circumferential arm measurement differences exist between ALT vs CSER or MLD vs CSER.  
There was a significant (p≤ 0. 05) main effect between ALT and MLD. Post-hoc analyses 
revealed differences in ECF with significantly greater volumes for ALT than MLD at baseline 
(p=0.016), 10 minutes (p=0.022) and 60 minutes (p=0. 009) post-intervention (Table 8). Mean 
ECF volume for CSER was significantly less than ALT at 10minutes (p=0.004) and significantly 
lower than MLD at 60 minutes (p=0.004). 
LBCQ and subjective preferences  
The results of the abridged LBCQ questionnaire of symptoms showed that for symptoms 
experienced during assessments, there were no significant differences between groups. The 
two most common symptoms reported in all three intervention sessions were swelling and 
heaviness. There was no clear consensus on the most preferred choice of intervention; 
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however, the majority (13/16) of participants preferred ALT (7/16) and MLD (6/16). The 
treatment that participants thought to be the most effective subjectively was ALT (10/16).  
Discussion  
There were two main objectives to this study. First, we wanted to determine if there would be a 
detrimental effect on limb volume (e.g. significant increase in ECF measured by BIS and limb 
volume by CM) following a single bout of each intervention treatment in women who had their 
compression garments removed for 48 hrs.  Secondly, we wanted to determine which of the 
three interventions if any, is most effective in reducing limb volume in the immediate (10-60 min) 
and short term (24-hour) post-intervention time period. The results of this study suggest would 
tend to suggest that the ALT intervention was the most effective of the three interventions in 
terms of significantly reducing ECF volume not only over time but also in comparison to the 
MLD intervention. In comparison, an earlier study involving ALT, Tidhar et al. (2010) had 
immediate mean volume reduction of 53.5ml immediately following the first ALT session, 
measuring with water displacement. With respect to MLD, post-intervention limb volume did not 
change. Although it is tempting to state that MLD maintained limb volume constant over time; 
however, without the comparison of a control group, we cannot equivocally state that MLD had 
any effect whatsoever. In agreement with our immediate findings for MLD, a study by Maher et 
al. (2012) where they combined MLD & compressive sleeve and compared it with MLD in a one 
session design measuring with BIS and perometry at 30min intervals for 2hours found there was 
no change in volume for either intervention. Similarly, CSER did not produce any ECF volume 
change at any of the post-intervention time points. Despite these findings with CSER, it is 
encouraging from a clinical perspective to observe that ECF did not increase in the short- term 
post intervention period. Similarly, a study by Moseley et al. (2007), where the intervention was 
a 10 minute gentle arm exercise with deep breathing, their findings indicated an immediate 
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median reduction of arm volume of 52mls (p=0.004) that was not sustained at the 60min mark 
where the median volume returned to baseline.  
Whether or not ALT or CSER will have a greater impact over the longer term (e.g. 6-8wk 
“training effect) remains to be seen. With respect to lymphatic system adaptations two studies 
investigating lymph clearance rates (CR) utilizing lymphoscintigraphy to measure lymphatic 
function at rest and during exercise found similar results. In the first study, Lane et al. (2007) 
divided the participants in to three groups 1) breast cancer survivors with BCRL (n=10), 2) 
breast cancer survivors with no LE (n=10) and 3) healthy controls (n=10), and implemented 
moderate intensity upper body exercise as an intervention and found similar increases in lymph 
clearance rates (CR) in the upper limbs for all three groups. Havas et al. (1997) demonstrated 
that along with increased CR of interstitial fluid during exercise, endurance trained healthy 
subjects had higher resting interstitial fluid CR than that found in the untrained healthy subjects. 
Consequently, the authors suggest that exercise may produce adaptations of the lymphatic 
system. Although there appears to be a training induced increase in the resting CR of the 
interstitial fluid, it is still unclear if theses changes are due directly to morphological changes in 
the lymphatic system. 
Limitations:  
As mentioned previously, there was no control group included in the design of this pilot study. 
Since this was designed to be a pilot study, we knew that the sample size used would 
underpower the study and prevent us from making any significant generalizations about our 
findings. In fact, one of the secondary hypothesis to this pilot study was to determine what 
sample size would be needed in order to adequately power the follow up study. By calculating 
standardized difference = target difference / standard deviation and referring to a nomogram 
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produced by Altman (Altman, 1991), we are able to determine that it would require 50 
participants to reach a suitable level of power (0.8).  
Normally, we would not have expected the baseline ECF volume measurements to be any 
different from one another prior to each intervention. However, this was not the case for the 
baseline ECF measurement prior to ALT which was statistically higher that the baseline MLD 
value. In a previous study involving ALT Tidhar et al. (2010) found that there was no correlation 
between initial arm edema and the reduction in the volume after the ALT intervention (linear 
correlation of 0.3, p>0.2). Perhaps the difference in baseline volume was related to the women 
refraining from wearing their compression garment or weather conditions it is difficult to know. 
Since the baseline measurements for ALT were done in a public pool setting, perhaps the hot 
humid environment of the public pool had a vasodilatory impact on the lymphedematous arm 
thereby increasing the volume of the ECF compartment. In a comparison of the two 
interventions (ALT & MLD) for the baseline ECF measures of the non-affected (NA) arms we 
found the mean ECF volume for ALT was 19ml greater than for the MLD mean baseline 
measure. Although a smaller magnitude of difference it does suggest that the ECF volume of 
the NA arm may have also been affected by the pool environment.  
It is important to note that none of the volume changes measured throughout this study 
exceeded the least significant change of 43.7ml for BIS measures of LE arm. This value of 
43.7ml was derived as a result of our precision calculations in the included manuscript 
(Determining the precision of dual energy x-ray absorptiometry and bioelectric impedance 
spectroscopy in the assessment of breast cancer-related lymphedema). The least significant 
change (LSC) is the smallest change between 2 measurements taken over time that must be 
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exceeded for the change to be considered true with 95% confidence.  Therefore we cannot 
state with confidence that the changes measured in this study exceeded measurement error. 
Another factor that may have influenced the effects of all of these interventions is the long 
standing lymphedema condition in many of these women, as indicated by the average time 
since lymphedema onset of 6.5 years. This evidence of chronicity along with only six of the 
participants reporting pitting suggests that the composition of many of the women’s LE limbs 
may have developed fibrotic tissue and excessive adipose deposits impacting the reducibility of 
the arm volume with these interventions. 
The time commitment for participants in this study was approximately 12 hours over a minimum 
of 5 weeks. Several potential participants declined to participate indicating they found the time 
commitment too onerous. This factor along with the physical activity requirement to fulfill the 
protocol may have deterred less motivated and/or less physically active LE patients from 
participating and therefore an overall recruitment bias may exist. Another limitation of this study 
is the lack of controls or accounting for participants’ daily activities during the 24 hour period 
immediately following the intervention before the final assessment. The activities of the 16 
women who participated in this study, during the 24hr period between assessments varied from 
staying at home resting, to assisting family in the hospital, to a day of physical work. 
Recommendations for future research:  
Although the results of this pilot study may lead to more questions than answers and do not 
allow any clear conclusions to be drawn, this study has set the stage for future studies on the 
topic. Studies to, investigate these same research questions with a greater sample size and 
more control over variables appear warranted. Another important study that is needed would be 
tracking ECF volume changes over longer periods for ALT and CSER with and without 
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compressive garments. A study design to build upon would be the research of Vignes et al. 
(2010) replacing MLD with ALT and or CSER; in their prospective study measured 4 groups 
over a four year period. The groups were 1) MLD, 2) compressive sleeve (CS), 3) MLD & CS 
and 4) MLD & compressive bandages (CB). As well more investigations into the physiological 
















CHAPTER 5: MANUSCRIPTS 
The first of the two manuscripts contained in this chapter of the thesis (Determining the 
precision of dual energy x-ray absorptiometry and bioelectric impedance spectroscopy in the 
assessment of breast cancer-related lymphedema) is based on a research project in which this 
author was involved in recruiting, organizing logistics, performing all measurements and data 
collection. This manuscript is a copy of an article published in Lymphatic Research and Biology 
© 2013 copyright Mary Ann Liebert, Inc.; Lymphatic Research and Biology is available online at: 
http://online.liebertpub.com. 
The research questions for this study are: 1) Are DXA and BIS technologies feasible 
assessment tools to measure tissue composition of lymphedematous upper limbs as diagnosed 
in the BCRL patient population? 2) Is excess fat mass present and detectable by DXA in 
affected upper extremities of patients with Stage I and/or Stage II lymphedema? 3) What is the 
precision of DXA in measuring fat mass in the upper extremities in this population? 4) What is 
the precision of BIS in detecting extracellular fluid in stage 1 and/or stage 2 lymphedema? In the 
reporting of the results from this research this manuscript goes into detail about the 
measurement protocols, the calculations involved in the derivation of arm and ECF volume as 
well as the precision of both BIS and CM.  
Being involved in this first research study allowed the author to gain familiarity with this specific 
patient population of women with BCRL and furthered the author’s experience with the required 
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Background: The composition of breast cancer-related lymphedema (BCRL) has been shown to 
evolve from the initial accumulation of fluid to the development of fibrotic lesions and abnormal 
fat deposition. Therefore precise and reliable assessments of BCRL are required to develop 
accurate staging and management. Although dual energy x-ray absorptiometry (DXA) and 
bioelectric impedance spectroscopy (BIS) have been used to assess BCRL no study has 
evaluated the precision of these two modalities in the same cohort.  Methods and Results: We 
determined the precision of DXA and BIS in lymphedematous (LE) and non-affected (NA) arms 
of 24 women with Stage II unilateral BCRL. Precision was calculated from the results of paired 
bilateral arm measurements obtained from DXA scans measuring fat, lean and bone mineral 
masses, BIS measuring extracellular fluid (ECF) and total fluid volume and circumferential tape 
measurements (CM) of the arms to calculate the anatomic volume. Precision error was 
expressed as the root mean square (RMS) of the coefficients of variation (%CV) and standard 
deviations (SD). Results: The precisions of DXA and BIS varied from 1.16% (DXA 
measurements of LE arm total volume) to 1.86% (BIS LE arm total fluid volume) and from 
0.95% (DXA lean mass of NA arm) to 1.72% (DXA BMC of NA arm). Precision of CM measures 
of arm volume were 1.71% CV for LE arm and 2.51% CV for NA arm. The fat and lean masses 
of the LE arm exceeded the NA arm by about 15% (p< 0.0001).  ECF and total fluid volume of 
LE arm was 22.6% and 19% greater than the NA arm (p< 0.0001), respectively.  Conclusion:  
For BCRL, these findings suggest that DXA and BIS are two measurement instruments that 
provide acceptable levels of precision for the measurement of arm lean mass, fat mass and 
ECF volume, respectively. 




BCRL breast cancer related lymphedema ECF extracellular fluid 
BIS  bioelectric impedance spectroscopy LE lymphedema 
BMC bone mineral content LSC least significant change 
CM circumferential measurements with tape measure NA non-affected 
DXA dual energy x-ray absorptiometry   
 
Introduction 
Breast cancer-related lymphedema (BCRL) can be mild to severe but often presents as a 
chronic, progressive multi-stage condition that is initially diagnosed by swelling of the arm(s) 
and/or the hand(s). The swelling is typically caused by an accumulation of protein-rich interstitial 
fluid that has been shown to occur in approximately 25% of women following surgical removal 
and/or radiation of the axillary lymph vessels and nodes (Petrek, Senie, Peters, & Rosen, 2001). 
BCRL can cause physical and psychological distress and negatively affects work and social 
functioning (Thomas-MacLean R, 2008), other clinical symptoms include pain and shoulder 
range of motion restrictions which have been shown to affect over 50% of breast cancer 
survivors (Lawenda, Mondry, & Johnstone, 2009). It is believed that the treatment-induced 
damage to the axillary region inhibits the clearing of intercellular fluid by the lymphatic system to 
the venous system thus exacerbating the lymphedematous condition (Devoogdt, Van Kampen, 
Gearts, Coremans, & Christiaens, 2010). Over time, the accumulation of lymph and the 
subsequent swelling may compromise normal tissue oxygenation as well as muscle and 
immune system response; predisposing the area to recurrent infections. Also associated with 
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chronic inflammation is an excess of fibroblasts and collagen deposition which lead to fibrotic 
lesions that may be found within the edematous tissues (Tassenoy A, 2009). Although not yet 
completely understood impairments to the lymphatic vessels coupled with chronic inflammation 
appear to alter the lymphatic system’s role in fat metabolism, which may result in the deposition 
of abnormal amounts of subcutaneous fat in lymphedematous arms (Alitalo, 2011). This 
progressive development may in fact compromise and challenge the current paradigms for 
assessment and treatment of BCRL. 
Current decongestive therapies (e.g. compressive bandaging, manual lymphatic drainage and 
remedial exercises) aid in the elimination of excess fluid in the extracellular fluid (ECF) space 
however, with the more advanced stages of BCRL, the standard decongestive therapies may 
prove to be ineffective in reducing the cumulative fat and fibrosis (Vignes S, 2006), (Armer & 
B.R., 2005). Unless other innovative forms of therapy are introduced, the advanced stages of 
BCRL will remain a chronic incurable condition (Cornish, et al., 2001), (Bar Ad, et al., 2010), 
(Piller & Carati, 2009) (Lymphology, 2009). Before other forms of therapy and treatment are 
even considered, clinicians and health care providers must be capable of discriminating and 
assessing the difference between the fluid and non-fluid (e.g. total arm mass including bone) 
compartments. Some of the most frequently used clinical methods (e.g. circumferential 
measurements and volume displacement of the arm) of assessment of BCRL fail to provide the 
sensitivity or are unable to differentiate between tissue types as well as fluid and non-fluid 
compartments. Having access to this information would assist in directing treatment plans. 
Techniques such as dual-energy x-ray absorptiometry (DXA) and bioelectric impedance 
spectroscopy (BIS) are two measurement devices that are gaining prominence and acceptance 
in the lymphedema research community with regards to their safety, ease of measurement and 
ability to estimate soft tissue and fluid components, respectively (Gjorup C, 2010), (Czerniec S. 
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A, 2010), (Paskett E.D, 2012), (Armer & B.R., 2005).There is little published information on the 
precision of these two instruments for edematous upper extremities, particularly when they are 
both derived from one cohort of women on the same day. The precision is important in that it 
defines the least significant change (LSC) in tissue composition and fluid levels in the affected 
arms of women as their lymphedema condition changes with treatment and over time. 
Furthermore, different forms of treatment therapies and interventions throughout the progressive 
stages of BCRL would necessitate the repeated use of DXA and BIS in the same patient cohort. 
Thus, the precision of DXA and BIS is absolutely essential in order to determine the true 
effectiveness of any treatment or intervention. Therefore, the aim of this observational pilot 
study was to determine the precision of the DXA and BIS devices and their clinical feasibility in 
estimating fat and lean masses and fluid volumes in lymphedematous (LE) and non-affected 
(NA) arms.     
Materials and Methods 
Between June 2010 and November 2011, 40 eligible patients visiting the Montreal General 
Lymphedema Clinic were invited to participate in this study. Twenty-four women with a clinical 
diagnosis of unilateral Stage II lymphedema were recruited from the clinic and written informed 
consent was obtained. Eligibility criteria for the study included: 1) females between 40-70 years 
of age, 2) BMI ≤ 30, 3) six months or more post-breast cancer treatment, 4) breast cancer 
Stages I-III in remission, 5) no significant chronic illness (e.g., congestive heart failure), 6) with 
unilateral Stage II lymphedema, 7) not pregnant, and 8) no history of involvement in sport 
involving unilateral upper extremity (e.g. tennis). Staging was determined according to the 
International Society of Lymphology criteria (Lymphology, 2009). The staging assessments 
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were performed by the clinic’s physician and physiotherapists who are all lymphedema 
specialists. 
All assessments took place at the McGill Nutrition and Performance Laboratory in Montreal. 
Participants were 57.2±7.8 years of age, 70.1±6.3kg in weight, and 162.1±6.7 cm in height and 
had a BMI of 26.7±2.6 kg/m².  All values are expressed as mean ±SD. Body weight was 
measured to the nearest 0.1kg using a digital scale (Amcells TBS Series, USA) and height was 
determined without shoes to the nearest 0.5cm using a wall mounted stadiometer.   
Total body DXA scans were performed with a Lunar Prodigy Advanced scanner (GE 
Healthcare, Madison, WI, software version 2006). Prior to each assessment session the 
measurement stability of the scanner was documented using the manufacturer supplied 
aluminum spine phantom. From the total body scans appendicular fat, lean and bone mineral 
content of both arm segments were identified and calculated with the region of interest 
extending from the gleno-humeral joint to the finger tips. Each measurement session began with 
two consecutive total body DXA scans with the patient supine on the DXA table. After the first 
scan the patient stood up and then was repositioned on the table for the second scan. Each 
scan took approximately 8-10 minutes. Using previously derived densities for: fat, (0.9gm/ml); 
lean mass, (1.1gm/ml); bone mineral, (1.85 gm/ml) the measured DXA tissue weights were 
transformed into estimated volumes using the following equation: v= m/d where v = volume, m = 
mass and d = density (Gjorup C, 2010), (Brorson H O. K., 2009). 
For the BIS (Model SFB7, ImpediMed Ltd., Brisbane, Australia) measurements, each participant 
laid supine on a non-conductive surface, with all limbs slightly abducted. The skin surface at the 
sites of electrode placement was thoroughly cleaned with alcohol swabs and 4 disposable dual 
tab electrodes were accurately placed with reference to anatomical markers. One dual tab 
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electrode was placed at each wrist next to the ulnar head extending to the dorsal surface of the 
hand, 1-2cm proximal to the metacarpo-phalangeal joint of the middle finger. The remaining two 
dual tab electrodes were placed at the ankle joint of each leg between the medial and lateral 
malleoli to the dorsal surface of the foot, 1-3cm proximal to the metatarso-phalangeal joint of the 
second toe. These locations were selected according to the manufacturer’s recommendations.  
A small constant current (200μA) was generated and passed between the electrodes spanning 
the body and the voltage drop between the electrodes provided a measure of impedance. The 
BIS measurements of both arms and total body took approximately 8-10 minutes. Ten minutes 
later after standing and removal of the electrodes, the patient was repositioned on the non-
conductive surface and a new set of electrodes were placed in the identical location as before. 
The BIS procedure was then repeated. Before each session a system test was run as per 
manufacturer’s recommendation. Participants were asked to fast and refrain from consuming 
any fluids for 4 hours prior to their appointments. 
The BIS system’s analysis software (Bioimp version 2.25, ImpediMed Ltd., Brisbane, Australia) 
fits a semicircular locus to the reactance vs resistance data at each frequency to give an 
estimate of resistance at a frequency of zero and infinite. For this analysis, the parameters were 
set as follows: a data rejection level of “none” (default setting) and an operator-chosen 
frequency range of 3 KHz-500 KHz was selected. This frequency range was chosen, after visual 
inspection of the first eight data sets and the frequency range adjustments revealed that 3 KHz-
500 KHz produced better curve fits of the data to the theoretical semicircular locus in all cases.  
The utility of the resistance values measured by BIS lies in the theory that at low frequencies the 
cell membrane is highly resistant thus; the electric current travels in the extracellular fluid 
surrounding the cells only whereas, at high frequencies the cell membrane is less resistant, and 
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the electric current travels in the intra and extracellular fluid and thus resistance estimated at a 
frequency of zero (Ro) represents ECF and resistance estimated at a frequency of infinity (R∞) 
represents  total fluid (Cornish, et al., 2001). Using the method published by Ward, Czerniec, & 
Kilbreath (Ward, Czerniec, & Kilbreath, 2009), the fluid volumes for arm ECF and arm total fluid 
were derived from the equation: V(volume) = p (arm L²/R),   where p= coefficient of resistivity, R 
= resistance (Ro or R∞ ) and L = length of arm, (where arm length was calculated as a proportion 
of height).  
Paired bilateral arm volume measurements were obtained by serial circumferential 
measurements (CM) to the nearest millimeter with a retractable no stretch soft tape measure 
(Juzo, Cuyahoga Falls, OH). The CMs were taken at the following five points on the arm: 1) the 
mid-point of the ulna styloid, 2)10cm proximal to the ulna styloid, 3) antecubital fossa, 4)10cm 
proximal to the antecubital fossa and 5) level with the axilla.  The volume of each segment or 
truncated cone was derived from the following expression: V = l (C1² + C1·C2 + C2²)/37.7, where 
l is the length of the segment, C1 and C2 are the circumferences of each end of the segment. 
The total volume of the arm was the summation of these segments (Taylor R, 2006). 
Each measurement session consisting of paired measures of all three measurement techniques 
and lasted approximately 60 minutes. All measurements with the DXA and BIS devices and the 
tape measure arm circumferential volume determinations were performed by one of the authors 
(AN) who had had two years of experience in the use of all three measurement methods.  
Statistical Analysis 
The percent coefficient of variation (%CV) and standard deviation (SD) were calculated for each 
paired bilateral arm measurements as follows: 
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SD = (d²/2) 0.5 and %CV = (SD/M) x 100 
where d denotes the difference between the two measurements and M denotes the mean.  
From these calculations the precision error also called technical error of measurement (TEM) 
was derived from the following expressions 
RMS-SD = (ΣSD²/N) 0.5 and RMS-%CV = (ΣCV²/N) 0.5     
where RMS is the root mean square of the paired measurements and N is the number of 
patients. 
The least significant change (LSC) is the smallest change between 2 measurements taken over 
time that must be exceeded for the change to be considered true with 95% confidence. This is 
expressed as 2.77 times precision; 2.77 x RMS-SD and 2.77 x RMS-%CV. Theoretically, it is 
limited to the device from which the precision was determined as the precision may vary with 
different devices (Shepherd JA, 2007).  
Paired t-tests were used to compare differences in variables (e.g., fat mass, lean mass, ECF, 
bone mineral content) between the lymphademetous (LE) and non-affected (NA) arms. 
Results 
Table 4 details the differences between the measurements of the LE and NA arms for the 24 
women obtained from DXA and BIS. The LE arm was significantly (p< 0.0001) greater than the 
NA arm for all the variables except the bone mineral content. The measured percent differences 
between LE and NA arms in this cohort of women with Stage 2 lymphedema ranged from 15% 
to 22.6%. To be noted is that the total arm volume derived from the fat, lean and bone mass 
DXA measurements and the CM of total volume yielded a similar percentage difference 
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between LE and NA arms. From the DXA measurements we found the FM of the LE arm was 
greater than the NA arm with a mean difference of 15.7% while the FFM of the LE arm was 
greater than the NA arm with a mean difference of 15.6%. As a point of reference, a recent 
retrospective study, using DXA to measure, involving 1240 healthy women ranging in age from 
20-80 found the FFM of the right arm was higher than the left with a mean difference of 5% in all 
age groups yet only a slight difference of FM between the left and right arms of women over 50 
years of age (Coin A, 2012). Table 4 also shows a change in the relation between LE and NA 
arms after their ECF volumes, as derived from the BIS, are subtracted from their lean mass 
volumes. There is a reduction in the percent difference from 15.6% to 8.7% between LE and NA 
arms for the FFM; this percent difference is still significant.  
The precision of the various measurements are listed in Table 5. Precision of DXA mass 
measurement for the LE arm varied from 1.28% CV (BMC) to 1.49% CV (lean mass) and for the 
NA arm the precision ranged from 0.95% CV (lean mass) to 1.72% (BMC). The precision of BIS 
measurements for LE arm were 1.65 % (ECF) and 1.86% (total fluid volume). For the NA arm 
BIS precision values were 1.51% (ECF) and 1.56% (total volume). Precision for the anatomic 
tape measurement of volume was 1.71% CV for LE arm and 2.51% CV for NA arm. From these 
determinations LSC at a 95% confidence level was calculated (Table 7). With respect to DXA fat 
mass, for example, a measured change ≥ 57.3g or a change in %CV ≥3.91 in the LE arm would 
indicate, with a 95% confidence level, a significant change in fat mass. The calculations of LSC 
at a 95% confidence level for BIS measures of LE arm were 43.7ml, 4.57%CV (ECF) and 




The findings of this study show that DXA and BIS can be used to determine differences in upper 
limb tissue composition and upper limb volume. We found no significant difference in precision 
of the DXA or BIS measurements between LE arms and NA arms. Our results show the total 
volume derived from DXA measurements and the CM total volume measurements yielded 
similar percentage differences between LE and NA arms. The discrepancy in the actual volume 
is attributed to the fact that there were different tissue volumes being measured in all three 
methods. For instance, the DXA field extended from the finger tips to the gleno-humeral joint, 
while the circumferential volume limits were from the wrist to several centimeters below the 
gleno-humeral joint and, the BIS measured from the wrist to an indeterminate point between the 
axilla and acromion. Importantly, although all three methods are not measuring the exact same 
volume, this should not affect precision. 
A relatively poor inter-subject (e.g., the arm position changing the shape of the arm) and inter-
tester (e.g., the degree of tightness with which the tape is applied) repeatability can influence 
the precision error of the measurements derived from the circumferential tape technique. 
Furthermore, the truncated cone method that is typically used to calculate arm volume includes 
the inaccurate assumption that limb segments are cone shaped and does not allow for uneven 
skin surface. In this study, the precision results for the anatomic tape measurement of volume 
were 1.71% CV for LE arm and 2.51% CV for NA arm. These coefficients of variation rank the 
CM measurements as the least precise of the three methods analyzed in this study. 
From a research or clinical perspective, with total volume as the only result obtainable from CM, 
this evaluation method has limited utility for the assessment or tracking of body composition in 
later stage BCRL. In contrast, the DXA measures give a breakdown of the tissue differences 
between limbs, thereby enabling the tracking of differences in fat and lean volume over time. 
44 
 
Clinically, the values for the LSC at a 95% confidence level calculated from the measured 
precision errors should serve as a guide to determine a significant change between two points 
in time such as when tracking the progression of this chronic condition. For example, as 
previously stated, a DXA measured change ≥ 57.3g of FM and/or BIS measured change ≥ 
43.7ml of ECF within the LE arm would indicate a significant change that may require a specific 
treatment or change in treatment plan. Lesser degrees of confidence enable smaller changes to 
be considered normal; e.g., the LSC for fat at a 95% level of confidence for the LE arm is 2.77 x 
1.41% = 3.9%, whereas for an 85% confidence the LSC is 2 x 1.41% = 2.8% (Table 5). 
It is well known caveat that different manufacturers, instrument models, and software versions 
as well as different operators are all likely to affect the precision and reproducibility of the DXA 
results (Guglielmi1 G, 2012), (Toombs RJ, 2012), (Baim S, 2005). It is important to note that the 
lean mass as measured by DXA includes not only muscle, but all the other tissue components 
except fat and bone mineral (e.g. water, proteins, glycogen, non-bone minerals etc.). There is a 
report wherein the DXA lean mass difference between LE arm and NA arm was attributed 
entirely to muscle without correcting for the presence of ECF (Brorson H O. K., 2009). Our 
finding of a change in the relation between LE arm and NA arm after the ECFs are subtracted 
from their respective lean mass volumes show a reduction in the percent difference between LE 
arm and NA arm lean mass from 15.6% to 8.7%. The difference is still significant and may be 
due primarily to a difference in muscle mass. The BIS measurements of ECF indicates that a 
considerable portion of that lean mass difference found in the DXA measurements can be 
attributed to the fluid component of the lymphedematous arms.  
Even though perometry and circumferential tape measurements are still the most commonly 
used clinical assessment techniques to identify the appearance of LE, other more sensitive and 
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reliable methods have been gaining recognition (Czerniec S. A, 2010),(Maher, 2012), (Cornish, 
et al. 2001). Over ten years ago, Cornish et al (2001) demonstrated the efficacy of BIS over CM 
in terms of its sensitivity and specificity in being a reliable measurement tool to determine the 
early detection of LE in 20 women up to 24 months following post-surgical procedures for breast 
cancer (Cornish, et al., 2001). More recently, BIS has been found to be more sensitive than 
perometry in determining more localized LE (Czerniec S.A, 2010). In fact, the lower level of 
detection of LE utilizing BIS has been shown to be approximately 35ml (Maher, 2012); a value 
that is very similar to the least significance difference (43.7mls) found in the present study. 
Taking these findings into account, it would appear that the BIS technique is sensitive, reliable, 
and has the precision to detect the onset of fluid change that would signal the early 
development of LE. However, for those women who progress through the various stages of LE, 
there may be a greater need and use for detection devices such as the DXA that we have found 
to be sensitive to soft tissue changes (e.g., adipose tissue) in this particular population. 
The calculations used to estimate fluid volumes with the impedance and resistance data 
collected with the BIS incorporates the assumption of constant coefficients of resistivity for the 
fluids. These coefficients of resistivity were derived from a cohort of women without 
lymphedema. Most likely as a result of the protein rich ECF and other resistive sensitive 
material (e.g., fat deposits) found in lymphedematous limbs, the coefficient of resistivity would 
not be the same as that for non-affected arms and thus may be a source of error in the fluid 
volume calculations for the lymphedematous arms derived from the BIS. More research appears 
warranted to determine to what extent the body composition of the arms of women with BCRL 
varies over time. Although our findings have shown that the BIS measurements are less precise 
than DXA, we wish to point out the fact that the difference in precision between the two 
instruments is relatively small. This should not detract from using the BIS since, unlike the DXA 
46 
 
scanner, tracking patients with the BIS gives information about the fluid in the limbs initially and 
over time. As well the BIS is portable making bedside assessments possible; the time involved 
in measurement is about half that of a DXA scan and the BIS system is a fraction of the cost of 
the DXA scanner. The clinical need for the DXA measurements lie in those cases of BCRL 
where the difference in fluid volume do not account for the better part of the difference in total 
limb volume. As well tracking patients using DXA measurements would open a window to 
observing if the fat content responds to traditional decongestive therapy. Hence, performing 
assessments of BCRL with DXA and BIS in concert will yield a more complete picture of the 
tissue composition and may influence treatment management. 
All the technical procedures in this study were conducted by one person and although this may 
be ideal, it does not reflect the clinical reality wherein the patient may be monitored with these 
procedures over time by different personnel. The inter-individual variation in precision was not 
an end point in this investigation. 
In conclusion, DXA and BIS are two tools with good precision for research and clinical 
assessment of breast cancer related lymphedema. This finding is essential for us to acquire 
greater insight into the changes in tissue composition occurring with the progression of BCRL 
and for the development of novel treatments for this chronic condition. 
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Table 4: Dual energy x-ray absorptiometry, multifrequency bioelectric impedance 
spectroscopy and circumferential tape measurement of arm volumes in women (n=24) 
with Stage II breast cancer related lymphedema 
Variable Lymphedema 
arm 
Non-affected arm P % difference 
DXA, fat mass (g) 1409 (298) 1214 (270) <0.001 15.7 
DXA, lean mass (g) 2100 (390) 1813 (177) <0.001 15.6 
DXA, BMC (g) 141 (17) 140 (17) 0.832 0.6 
DXA, total arm volume (ml) 3531 (574) 3070 (385) <0.001 15.0 
BIS, EFC (ml) 927 (165) 756 (89) <0.001 22.6 
BIS, total fluid volume (ml) 1806 (342) 1517 (163) <0.001 19.0 
Circumferential arm volume (ml) 2432 (386) 2135 (304) <0.001 13.8 
Lean mass volume minus ECF(ml) 1010 (161) 929 (130) 0.048 8.7 
All values are expressed as mean ± standard deviation (SD).  BMC: bone mineral content; DXA: dual 











Table 5: Precision expressed as root mean square (RMS) of the variables in the 
lymphedematous and non-affected arms 
Variable Lymphedema arm 
RMS-SD           RMS-%CV 
(LSC)                     (LSC) 
Non-affected arm 
RMS-SD gm         RMS-%CV    
(LSC)                    (LSC) 
DXA fat mass(g) 20.7 (57.3)             1.41 (3.9)                            12.4 (34.3)           1.05 (2.9) 
DXA lean mass (g) 30.6 (84.7)             1.49 (4.3) 17.4 (48.2)            0.95 (2.6)  
DXA bone mineral content (g)  1.8 (5.0)               1.28 (2.8)  2.5 (6.9)              1.72 (4.8) 
DXA arm volume (ml) 42.0 (116)              1.16 (3.2) 18.3 (50.7)            0.62 (1.7) 
BIS extracellular fluid (ml) 15.8 (43.7)             1.65 (4.6) 11.5 (31.8)            1.51 (4.2) 
BIS total fluid (ml) 32.6 (90.3)             1.86 (5.2) 23.2 (64.3)            1.56 (4.3) 
Circumferential arm volume (ml) 44.8 (124)              1.71 (4.7) 52.3 (145)             2.51 (6.9) 
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The incidence of breast cancer-related lymphedema (BCRL) is approximately 30% for women 
who undergo breast cancer treatment (e.g. mastectomy, axillary node dissection and/or 
radiation treatment) (Williams A, 2005). The resulting physical symptoms (e.g., aching, 
numbness, pain and fatigue), functional outcomes (e.g., decreased strength and range of 
motion), and the need to wear compressive garments on a daily basis for prolonged periods of 
time place a persistent and significant burden on the quality of life of these survivors and 
creates the need for effective treatment interventions. Although there are a growing number of 
different treatment interventions, little is known about the efficacy of these treatments in terms of 
either maintaining or reducing BCRL. Therefore, the study objectives were: 1) To assess the 
immediate and short-term effects in extracellular fluid (ECF) following a single bout of activity 
from three different interventions for BCRL (e.g., manual lymphatic drainage (MLD), aqua 
lymphatic therapy (ALT), and a Casley-Smith based exercise routine (CSER), 2) To determine 
which of the three interventions is most effective in maintaining or reducing limb volume over a 
24 hour period, 3) To identify any changes in physical symptoms after each intervention and, 4) 
To ascertain which of the three interventions the women prefer. Methodology: The participants 
were sixteen women between the ages of 35 and 75 with Stage II lymphedema. All participants 
were required to refrain from wearing their compression garments during interventions as well 
as 24 hrs before and after each intervention. Each of the 3 interventions was completed once 
and lasted approximately 45min. Procedures: Bilateral limb measurements to estimate 
changes in limb volume were obtained using bio-impedance spectroscopy (BIS) and 
circumferential arm measures (CAM). The Lymphedema Breast Cancer Questionnaire (LBCQ) 
was administered to subjectively gauge any change in symptoms. After completion of the final 
intervention, a questionnaire on intervention preference was administered. Results: There were 
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no significant increases in ECF or CAM following a single bout of each intervention over the 24 
hr recovery period. Of the three interventions, ALT was the only intervention that showed a 
significant (p≤0.05) decrease in ECF from baseline to 20-24hrs post-intervention. When 
compared to the MLD, the ALT intervention demonstrated a consistent 3.31% greater (p=0.038) 
reduction in ECF volume over 24hrs. Comparing physical symptoms experienced by the 
participants in each of the three interventions, there was no significant differences found pre and 
post interventions. The majority of women (13/16) preferred ALT (7/16) and MLD (6/13).  
Conclusion: In the immediate to short-term post-intervention period, these preliminary findings 
show that none of the three interventions increased ECF and physical symptoms in women who 
had removed their compressive garments Thus, ALT and CSER appear to be safe exercise 
interventions in women with BCRL; however, ALT was the most effective intervention in 
reducing limb volume over short term (24 hrs) post-intervention period.  
Abbreviations 
ALT Aqua Lymphatic Therapy DXA dual energy x-ray absorptiometry 
BCRL breast cancer related lymphedema ECF extracellular fluid 
BIS  bioelectric impedance spectroscopy LBCQ Lymphedema Breast Cancer Questionnaire 
CAM circumferential arm measurements  LE Lymphedema 
CDT Complete (or Complex) 
Decongestive Therapy 
NA non-affected 





Breast cancer-related lymphedema (BCRL) is an incurable condition that results in swelling of 
the arm(s), hand(s) and /or breast caused initially by an accumulation of protein-rich interstitial 
fluid with the possibility of the long-term build-up of subcutaneous fat deposits and fibrous 
matrices. This fluid increase could result from the treatment of breast cancer, such as surgical 
intervention (e.g. radical mastectomy and axillary node dissection) and/or radiation treatment. 
Velanovich & Szymanski (1999) revealed that for a significant number of patients with BCRL the 
disorder is physically as well as emotionally disabling. The adverse physical effects (e.g., 
stiffness, numbness, and fatigue) and negative functional outcomes (e.g., decreased strength 
and range of motion) place a constant and significant burden on women with BCRL that 
worsens their quality of life (Passik, 1998). 
 According to the Position Statement of the National Lymphedema Network, the most 
appropriate course of treatment upon diagnosis of BCRL is Complete (or Complex) 
Decongestive Therapy (CDT) which consists of two phases (Network, 2009). Phase I focuses 
on volume reduction of the lymphedematous limb and attending to any skin irritations and/or 
infections which are common sequelae to impaired lymphatic function.  This phase comprises 
an intensive 2-6 week course utilizing four treatment methods: 1) manual lymphatic drainage 
(MLD); 2) skin care; 3) daily compression bandaging and 3) remedial exercises. This phase 
continues until the limb volume reduction reaches a steady state plateau at which time the 
patient moves on to Phase II. Phase II of the CDT protocol is considered to be a maintenance 
period. The patient is responsible for Phase II and will need to take self-directed measures for 
the rest of their lives to maintain the limb volume reduction that was achieved in Phase I. 
Standard practice for clinicians treating BCRL is to educate the patient throughout Phase II on 
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skin care, self massage and home-based exercises (Network, 2009). It is believed that the 
absence of any self-directed measure to control LE and its symptoms would typically result in 
the worsening of the BCRL condition (Bar Ad, et al., 2010), (Johnstone, 2006). Despite the 
education and advice given to patients diagnosed with BCRL concerning the importance of the 
maintenance phase of BCRL treatment, there is evidence to show that some patients have 
difficulty adhering to the Phase II program resulting in the progression of lymphedema to levels 
observed prior to CDT (Vignes, 2011). One of the complications that some patients encounter 
during their maintenance program is the adverse effects of wearing compressive garments. For 
instance, compression of the arm garments worn at the wrist can cause hand swelling, and 
friction from the seams of the garment can cause irritation of the skin and pain (Vignes, 2011).  
In Quebec, the cost of lymphedema treatments is not covered by Medicare. According to a 
recent publication on the Quebec government website the cost of compressive garments alone 
is $1,166 per person per year ((INESS), 2011). This does not include the cost of treatment 
interventions. The cost of one MLD (skin massage) treatment ranges between $80- $100. Since 
LE in most cases is a chronic lifelong condition, the accumulated expenses for regular 
treatments clearly place a serious economic burden on the patient. Although MLD has been 
shown to enhance the effects of compression treatments (Lasinski B, 2012), this treatment has 
been found to be ineffective in maintaining limb volume over the long term (Vignes, 2011). For 
those with BCRL who have limited financial resources or intolerance to compressive sleeves 
their lifelong, self-care program may be highly dependent upon self-massage and remedial 
exercises as a means of maintaining their limb volume. Consequently, there should be a 
particular importance and emphasis on the types of interventions available to these women. 
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Using BIS and CM to assess changes in limb volume and self-reported symptoms as outcome 
measures, this study investigates the short-term efficacy of three interventions for the treatment 
of BCRL: 1) Manual Lymphatic Drainage (MLD), 2) Aqua Lymphatic Therapy (ALT) and 3) 
Casley-Smith based Exercise Routine (CSER).  
METHODS 
Experimental Design: A repeated measures crossover design (“3 treatments, 4 periods”) was 
chosen to reduce the chance of variation between individuals that may skew the results and 
also because this design is most suited for the comparison of smaller groups. 
Participants: Recruit of the study population took place at the McGill University Health Center 
(MUHC) Lymphedema Clinic between September 2011 and May 2012. Nineteen women who 
were diagnosed with Stage II unilateral BCRL were recruited from the 35 eligible participants 
visiting the Clinic. Written informed consent was obtained from all participants. Eligibility criteria 
for the study included: 1) females between 35-75 years of age, 2) BMI ≤ 45, 3) six months or 
more post-breast cancer treatment, 4) breast cancer Stages I-III in remission, 5) absence of any 
significant chronic cardiovascular, metabolic, and neurological diseases, 6) the presence of 
unilateral Stage II lymphedema, 7) not pregnant, 8) no aversion to swimming pool activities, 9) 
completion of Phase I of CDT, 10) willingness to refrain from wearing a compression garment 
for 24 hours prior to and following each intervention. Lymphedema staging was determined 
according to the International Society of Lymphology criteria (Lymphology, 2009).The staging 
assessments were performed by the clinic’s physician and physiotherapists who are 
lymphedema specialists. 
Of the 19 women recruited, three withdrew (two found time commitment too great, one 
experienced minor shoulder discomfort after the CSER intervention and was treated by a 
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physiotherapist) resulting in 16 women completing the protocol. See Table 6 for a description of 
the participant characteristics.   
Protocol 
The assessments involved the LBCQ symptom questionnaire, bilateral limb volume 
measurements for ECF using bioelectrical impedance spectroscopy (BIS) and circumferential 
arm measures (CM). The unaffected limb was measured to serve as an internal control. 
Participants were assessed before and after each treatment intervention. For this repeated 
measures crossover design, all women participated in each of the three treatment interventions 
over a five -seven week period, with a 10 day minimum “washout” interval in between 
interventions. All participants were asked to refrain from wearing a compression garment during 
the intervention as well as 24 hours prior to and following each intervention (for a total of 48 
consecutive hours). The MLD and CSER interventions took place at the McGill Nutrition and 
Performance Laboratory of the McGill University Health Centre (MUHC). The ALT intervention 
took place in the swimming pool at the Montreal YM-YWHA and was performed by a 
physiotherapist from the MUHC. The MLD sessions were performed by a certified Vodder 
method trained therapist.  All interventions were performed by trained lymphedema specialists 
and each session lasted for 45 minutes. All measurements using the BIS device and the CAM 
tape measure were performed by one of the authors (AN) who had had three years of 
experience in the use of both measurement methods.   
Interventions                                                                                                                                         
ALT is a self-treatment in a group setting. ALT is based on the Casley-Smith remedial exercise 
principles. The method uses the anatomical principles of the lymphatic system and the 
properties of water to achieve the goals of lymphedema therapy. The water temperature ranges 
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from 31°C to 33°C. Water’s property of buoyancy aids in elevating the limbs and thus allowing 
for the performance of exercises and self massage with minimal effort (Tidhar D., 2010). The 
possible mechanism behind this treatment is twofold: 1) incorporating water’s hydrostatic 
property to create a pressure gradient enhancing directional lymphatic flow, and 2) the viscosity 
of water providing resistance with movement for a gentle massage or more vigorous 
movements in specific directions for strengthening and encouraging the extrinsic pumping of the 
lymphatic vessels.  
The MLD method of massage stretches the skin and incorporates gentle rhythmic circular 
movements in specific directions, interspersed with rest periods, using an approximate pressure 
of 30mmHg which varies according to the edema (e.g., increased pressure for breakdown of 
fibrotic tissue). The suggested mechanism of this intervention to encourage lymph flow is 
threefold: 1) shunting the lymph with slowly increasing pressure, 2) an attempt to create 
pumping by the rhythmic pressure, rest (no pressure) movements, and 3) an attempt to 
stimulate lymphatic vessel contraction with the stretching of the skin  (Williams A., 2010), 
(Kasseroller, 1998). 
CSER is a gentle (low intensity) 45 minute exercise routine that incorporates breathing, slow 
rhythmic mild isotonic contractions of the arm muscles interspersed with self-massage to 
promote regional lymphatic fluid movement and venous outflow (Casley-Smith J.R, 1998). The 
mechanism for this method is proposed to be the systematic application of varying pressures 
through movements to specific areas with the intent to create a pressure gradient to encourage 






Anthropometry: Before each intervention session body weight was measured to the nearest 0.1 
kg using a digital scale (Amcells TBS Series, USA). Height was measured without shoes to the 
nearest 0.5cm using a mechanical stadiometer (Seca). Body mass index (BMI) was calculated 
as weight (kg) divided by height (m) squared (kg/m²). 
To minimize a possible order effect, participants were assigned to receive the three 
interventions in one of five sequences. The pre-intervention symptom questionnaire was 
administered and bilateral limb volume measurements were taken immediately prior to each 
intervention. The post-intervention assessments included a 12 question abridged version of the 
LBCQ and were done at 10min, 60min and 20-24 hrs. 
Bilateral changes in limb volume were measured using the following two methods:                                  
1) Bioelectrical impedance spectroscopy (BIS): This method has been shown to be highly 
reliable with good precision for the assessment of BCRL (Cornish, et al., 2001), (Newman A, 
2013). The BIS system used in this protocol was the ImpediMed SFB7. For the study analysis, 
the system’s software (Bioimp version 2.25, ImpediMed Ltd., Brisbane, Australia) was used with 
the parameters set as follows: a data rejection level of “none” (default setting) and an operator-
chosen frequency range of 3 kHz-500 kHz. These settings were previously determined to be the 
most appropriate for this population (Newman A, 2013). Participants were in a supine position 
on a non-conductive table with their arms slightly abducted, palms down, and with legs slightly 
apart. The skin was wiped with an alcohol swab and allowed to dry. Four electrodes were 
applied to the skin in accordance with manufacturer’s recommendations. With four leads 
attached to the electrodes, a small constant AC current (200μA) was passed from hand to foot 
and the drop in voltage was measured. The measures of impedance (opposition to the flow) of 
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the electric current through the body fluids are used to calculate the volume of extracellular and 
intracellular fluid (Ward, Czerniec, & Kilbreath, 2009).  
2. Circumferential arm measures (CM): This method makes use of a tape measure to obtain 
circumferential measures from the wrist to axilla at 10-cm intervals. Arm volumes were 
calculated by summing the various segment volumes derived from the truncated cone formula 
(Karges, 2003). CAM is a commonly used method for monitoring limb volume in the treatment of 
lymphedema and has been found to be highly reliable and correlates well with water 
displacement that is presently recognized as the clinical 'gold standard' method for limb volume 
measurement (Gjorup C, 2010), (Czerniec S. A, 2010), (Maher, 2012).The assessor was 
blinded to previous measurements by using a new data collection sheet for each set of 
measures. A more detailed description of the measurement protocols can be found in our 
previously published work (Newman A, 2013). 
These assessment periods lasted 10-20minutes and were done pretreatment and at 10min, 
60min and 20-24 hrs following each treatment intervention. 
Data Analysis 
The statistical package used was NCSS Statistical Software (version 7.1.17 Kaysville, Utah). 
The analysis done was a 3 (interventions) x 4 (time periods) repeated measures analysis to 
estimate the variance among the volume measurements for each of the three treatment 
interventions. A p ≤ 0.05 was used to determine if the variance estimate was considered to be 
statistically significant. When a p-value of ≤ 0.05 was obtained, the Tukey-Kramer Multiple-
Comparison post-hoc test was run to determine significant differences between individual 





Within group differences: There were no significant changes from baseline ECF at any of the 
measured time points (10 min, 60min, 24 hrs) following MLD or CSER. Of the three 
interventions, only ALT had a statistically significant (p≤ 0.05) change from baseline in ECF 
volume (26.9mls) at the 24-hour post-intervention measurement period (Table 7).  
Between group differences: In comparing the ALT vs MLD interventions from baseline to 20-
24hrs, ALT has a 3.3% greater (p=0.038) mean percentage ECF volume change than MLD at 
20-24 hours (Table 8). No other ECF differences exist between ALT vs CSER or MLD vs CSER. 
With respect to circumferential arm measurements, there was a significant difference (p=0.021) 
in the percentage change between ALT and MLD at 10 min post intervention. No other 
circumferential arm measurement differences exist between ALT vs CSER or MLD vs CSER.  
There was a significant (p≤ 0. 05) main effect between ALT and MLD. Post-hoc analyses 
revealed differences in ECF with significantly greater volumes for ALT than MLD at baseline 
(p=0.016), 10 minutes (p=0.022) and 60 minutes (p=0. 009) post-intervention (Table 9). Mean 
ECF volume for CSER was significantly less than ALT at 10minutes (p=0.004) and significantly 
lower than MLD at 60 minutes (p=0.004) see Table 9. 
Abridged LBCQ questionnaire and subjective preferences  
The results of the abridged LBCQ questionnaire of symptoms showed that for symptoms 
experienced during assessments, there were no significant differences between groups. The 
two most common symptoms reported in all three intervention sessions were swelling and 
heaviness. There was no clear consensus on the most preferred choice of intervention; 
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however, the majority of participants preferred ALT (7/16) and MLD (6/16). The treatment that 
participants thought to be the most effective subjectively was ALT (10/16).  
DISCUSSION  
There were two main objectives to this study. First, we wanted to determine if there would be a 
significant increase in ECF measured by BIS and limb volume by CM following a single bout of 
each intervention treatment in women who have had their compression garments removed for 
48 hrs.  Secondly, we wanted to determine which of the three interventions if any, is most 
effective in reducing limb volume in the immediate (10-60 min) and short term (24-hour) post-
intervention time period. The results of this study suggest would tend to suggest that the ALT 
intervention was the most effective of the three interventions in terms of significantly reducing 
ECF volume not only over time but also in comparison to the MLD intervention. In an earlier 
study involving ALT, Tidhar et al. (2010) had a mean volume reduction of 53.5ml measured with 
water displacement immediately following the first ALT session. With respect to MLD, post-
intervention limb volume did not change. Although it is tempting to state that MLD maintained 
limb volume constant over time; however, without the comparison of a control group, we cannot 
equivocally state that MLD had any effect whatsoever. However, in a study by Maher et al. 
(2012), MLD with the compressive sleeve was compared to MLD alone found there was no 
change in volume for either intervention at 30 min intervals for 2 hrs using BIS and perometry. 
Similarly, CSER did not produce any ECF volume change at any of the post-intervention time 
points. Moseley et al. (2005) completed a brief 10 minute gentle arm exercise with deep 
breathing and found an immediate median reduction of arm volume of 52mls (p=0.004) that was 
not sustained at the 60min mark when the median volume returned to baseline. Taking into 
account the three treatments, it is encouraging from a clinical perspective to observe that ECF 
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did not increase in the short- term post intervention period. Whether repeated sessions of ALT 
or CSER will have a greater impact on the limb volume of persons with BCRL over the longer 
term remains to be seen.  
Limitations: As mentioned previously, there was no control group included in the design of this 
pilot study. Since this was designed to be a pilot study, we knew that the sample size used 
would underpower the study and prevent us from making any significant generalizations about 
our findings. In fact, one of the secondary hypothesis to this pilot study was to determine what 
sample size would be needed in order to adequately power the follow up study. By calculating 
standardized difference = target difference / standard deviation and referring to a nomogram 
produced by Altman (Altman, 1991), we are able to determine that it would require 50 
participants to reach a suitable level of power (0.8).  
Normally, we would not have expected the baseline ECF volume measurements to be any 
different from one another prior to each intervention. However, this was not the case for the 
baseline ECF measurement prior to ALT which was statistically higher that the baseline MLD 
value. In a previous study involving ALT, Tidhar et al. (2010) found that there was no correlation 
between initial arm edema and the reduction in the volume after the ALT intervention (linear 
correlation of 0.3, p>0.2). Perhaps the difference in baseline volume prior to ALT was related to 
the women refraining from wearing their compression garment; however, this seems unlikely 
since we did not see any similar increases in baseline BIS prior to the other interventions. 
Another limitation to the research design was in not measuring the arm volume of the 
participants immediately after removing their compressive sleeves. Since the baseline 
measurements for ALT were done in a public pool setting, it is reasonable to assume that 
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perhaps the hot humid environment of the public pool had a vasodilatory impact on the 
lymphedematous arm thereby increasing the volume of the ECF compartment.  
The time commitment for participants in this study was approximately 12 hours over a minimum 
of 5 weeks. Several potential participants declined to participate indicating they found the time 
commitment too onerous. This factor along with the physical activity requirement to fulfill the 
protocol may have deterred less motivated and/or less physically active LE patients from 
participating and therefore an overall response bias may exist. Another limitation of this study is 
the lack of controls for participants’ daily activities during the 24 hour period immediately 
following the intervention before the final assessment. The activities of the 16 women who 
participated in this study, during the 24hr period between assessments varied from staying at 
home resting, to assisting family in the hospital, to a day of physical work. 
Recommendations for future research  
This study has set the stage for future studies on the topic of remedial exercise interventions in 
women with Stage II lymphedema. We have been able to determine what sample size is 
needed for a larger and better powered investigation. Since the present study focused on the 
immediate short-term effects of each intervention, we now need to track potential ECF volume 
changes over longer periods for ALT and CSER with and without compressive garments. A 
longitudinal study design by Vignes et al. (2010) could serve as a model whereby we will 
examine the long- term post intervention changes following ALT and CSER with and without 






For women with Stage II BCRL, ALT and CSER interventions as well as MLD appear to be safe, 
show no increase in ECF or physical symptoms, despite the fact that these women had 
removed their compression sleeve for 48 hrs. Although ALT appears to be the most effective 
intervention in terms of reducing limb volume over a 24 hour period, this finding should be 
viewed with some caution since this change appears to be mediated by yet an unexplained 
elevated baseline BIS value. Clearly demonstrating the existence of affordable intervention(s) 
that are effective in either reducing or at least maintaining the volume of their lymphademetous 
limb may assist women with BCRL with their lifelong challenges. 
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All values are expressed as mean ± standard deviation (SD);                                                                       
ALND: Axillary lymph node dissection; BMI: Body mass index;                                                                           









Age (SD) 60.23 (7.21) 
Weight (kg) (SD) 74.9 (15.04) 
BMI (kg/m²) (SD) 29.62 (4.86) 
Time since BCa Tx (months) (SD) 102.7(82.80) 
Time since LE Dx (months)(SD) 78.8(73.40) 
Breast cancer treatment 
Radiotherapy (n)  16 
Chemotherapy (n) 15 
ALND only (n) 3 
Lumpectomy (n) 7 
Mastectomy (n) 6 
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Table 7: Effects of three treatment interventions on absolute changes in ECF volume 
(mls) 
All values are expressed as mean ± standard deviation (SD); N=16/treatment; *: significant change from 












 Pre-treatment Post-treatment 
Treatment 0 minutes 10minutes 60 minutes 20-24hours 
ALT 883 (188) 881 (202) 873 (198) 856 (200)* 
MLD 856 (189) 855 (180) 845 (180) 868 (201) 
CSER 858 (202) 845 (192) 849 (198) 858 (213) 
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All values are expressed as mean ± standard deviation (SD);                                                                                                                                                                                
* denotes significant difference (p ≤ 0.05) from baseline;                                                                                                           
ALT: Aqua Lymphatic Therapy; CSER: Casley-Smith Exercise Routine;                                                                                               







N=16 Time (min) MLD (ml) CSER (ml) 
ALT 0 27.8 (0.016)* 15.8 (0.215) 
ALT 10 32.3 (0.022)* 31.2 (0.004)* 
ALT 60 34.7 (0.009)* 15.7 (0.607) 
ALT 1200 9.6 (0.396) 9.6 (0.445) 
MLD 0 --------------- 11.9 (0.357) 
MLD 10 --------------- 1.06 (0.912) 
MLD 60 --------------- 18.9 (0.004)* 
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Table 9: A comparison of treatment interventions measured in percentage changes from 
baseline ECF over time using bioelectric impedance spectroscopy 
 
All values are expressed as mean ± standard deviation (SD); * denotes significant difference (p ≤ 0.05) 
from baseline; ALT: Aqua Lymphatic Therapy; CSER: Casley-Smith Exercise Routine; ECF: extracellular 









 Pre treatment Post-treatment 
Treatment 
Comparison 
Time (0 minutes) 10 minutes 60 minutes 20-24 hours 
ALT vs MLD 0 0.208 (0.876) -0.823 (0.394) -3.308 (0.038)* 
ALT vs CSER 0 1.475 (0.201) -0.989 (0.302) -2.861 (0.069) 
MLD vs CSER 0 1.266 (0.091) -0.166 (0.867) 0.494 (0.818) 
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Table 10: A comparison of treatment interventions measured in percentage changes from 













All values are expressed as mean ± standard deviation (SD); * denotes a significant (p ≤ 0.05) difference;    
ALT: Aqua Lymphatic Therapy; CMvol: Circumferential measures, limb volume; CSER: Casley-Smith 
Exercise Routine; MLD: Manual Lymphatic Drainage 
 
 
N=16 Time (min) MLD-CMvol 
(percentage points) 
CSER- CMvol  
(percentage points) 
ALT- CMvol 0 0 0 
ALT- CMvol 10 1.868 (0.021)* -0.496 (0.577) 
ALT- CMvol 60 -1.186 (0.211) -1.826 (0.082) 
ALT- CMvol 1200-1440 -0.509 (0.549) -0.093 (0.914) 
MLD- CMvol 0 ------------------ 0 
MLD- CMvol 10 ------------------ -0.669 (0.354) 
MLD- CMvol 60 ------------------ -0.640 (0.458) 




These findings suggest that ALT was the most effective intervention in reducing limb volume 
over a 24 hour period. However, in light of the small sample size and the results of significantly 
greater ECF volume for the ALT group at baseline, there is reason to question the results rather 
than draw any conclusions. There is a definite need for research studies similar to this one with 
a larger sample size and more controls. Improvements to the research design of this study 
would include a sample size of 50 or more participants a control group each wearing a 
compressive sleeve, tracking the activities of the participants over the 48 hours that the 
participants were not wearing their compressive sleeves, a training session for the two exercise 
interventions, and measurements pre and post ALT to be taken in an environment similar to the 
environment where the other two interventions took place. Ideally, if feasible to measure again 
48 hours post intervention to see if more would be revealed about the residual effect of each of 
the three interventions. 
 This study has set the stage for future studies on the topic of exercise interventions in women 
with Stage II lymphedema. We have been able to determine what sample size is needed for a 
larger and better powered investigation. Since the present study focused on the immediate 
short-term effects of each intervention, we now need to track potential ECF volume changes 
over longer periods for ALT MLD and CSER with and without compressive garments.  
Women with BCRL live with many challenges. Clearly demonstrating that there exists 
inexpensive intervention(s) that are effective in reducing or maintaining the volume of their 
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Which hand do you write with?                                  _________________ 
 
Which arm, hand is affected by lymphedema?          ________________ 
 
When was your lymphedema diagnosis?                   _________________ 
 
When were you treated for breast cancer?               __________________ 
 









Lymphedema and Breast Cancer Questionnaire (LBCQ) 
ID Code #_______                                                             Interview Date ________ Staff ID____ 
Answer all questions you understand. Do not answer questions that have any words you do not 
understand. Circle any words you do not know. Lymphedema means swelling of the arm, hand, 
shoulder or upper body on the side where your cancer was first treated. Now refers to today or 
in the past month.  
Which side of your body was treated for breast cancer?  
Left __ Right __ Both __  
Questions about changes that have happened to your arm or body in the last month.  
Have you had a change in arm size?  
                Larger __ Smaller __ No change __  
Have you had a change in shoulder size?  
                Larger __ Smaller __ No change __  
 Have you had a change in neck size?  
                Larger __ Smaller __ No change __  
Have you had a change in how your sleeve fits?  
               Looser __ Tighter __ No change __  
Have you had a change in how your sleeve cuff fits?  
81 
 
               Looser __Tighter __ No change __  
Have you had a change in how your ring fits?  
               Looser __ Tighter __ No change __  
The following questions pertain to your experiences with movement, use, and sleep now* and 
during the past year: * Now refers to today or in the past month. 
Do you have limited movement of your...  Now                                      
If yes, please describe  
During Past Year            
If yes, please describe.  
8. Shoulder?  No  __  
Yes __  
No  __  
Yes __  
9. Elbow?  No  __  
Yes __  
No  __  
Yes __  
10. Wrist?  No  __  
Yes __  
No  __  
Yes __  
11. Fingers?  No  __  
Yes __  
No  __  
Yes __  
12. Does your arm or hand feel weak?  No  __  
Yes __  
No  __  
Yes __  
13. As part of your job, are you 
required to do some action with your 
arm or hand over and over?  
No  __  
Yes __  
No  __  
Yes __  
14. Do you need pillows to support 
and raise your arm?  
No  __  
Yes __  
No  __  
Yes __  
15. Are you unable to sleep through 
the night because your arm is not 
comfortable?  
No  __  
Yes __  
No  __  
Yes __  
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ID Code #_______                                                             Interview Date ________ Staff ID____ 
The following    questions pertain to arm, breast, and chest symptoms now* and during the past 
year: * Now refers to today or in the past month.                                                  





What action you did for this 
symptom: Please describe.  
 
16. Tenderness?  No  __  
Yes __  
No  __  
Yes __  
No action __  
Action:  
17. Swelling?  No  __  
Yes __  
No  __  
Yes __  
No action __  
Action:  
18. Swelling with pitting*?  
 
No  __  
Yes __  
No  __  
Yes __  
No action __  
Action:  
19. Redness?  No  __  
Yes __  
No  __  
Yes __  
No action __  
Action:  
20. Blistering?  No  __  
Yes __  
No  __  
Yes __  
No action __  
Action:  
21. Firmness/tightness?  No  __  
Yes __  
No  __  
Yes __  
No action __  
Action:  
22. Increased temperature in your arm? No  __  
Yes __  
No  __  
Yes __  
No action __  
Action:  
23. Heaviness?  No  __  
Yes __  
No  __  
Yes __  
No action __  
Action:  
24. Numbness?  No  __  
Yes __  
No  __  
Yes __  
No action __  
Action:  
25. Stiffness?  No  __  
Yes __  
No  __  
Yes __  
No action __  
Action:  
26. Aching?  No  __  
Yes __  
No  __  
Yes __  
No action __  
Action:  
27. Chest wall swelling?  No  __  
Yes __  
No  __  
Yes __  
No action __  
Action:  
*Pitting: when you press firmly on your skin and the dent stays long enough to feel it when you slide the 




ID Code #_______                                                             Interview Date ________ Staff ID____ 
 
31. What is your birthday? ____/ ____/ ______  
32. What is the highest year of school you attended? ______  
33. What is your height? ______  
34. What is your weight? ______  
35. How much did you weigh 6 months ago? ______  
36. How much did you weigh 1 year ago? ______ 
37. Diagnosis with breast cancer______________________________ Date _________  
38. Drugs (Chemotherapy) ___________________________________ Date ________ 
39. Surgery_______________________________________________ Date ________ 




What action you did for this 
symptom: Please describe.  
 
28. Breast swelling?  No  __  
Yes __  
No  __  
Yes __  
No action __  
Action: 
29. Pockets of fluid develop?  No  __  
Yes __  
No  __  
Yes __  
No action __  
Action:   
30. Other symptoms  No  __  
Yes __  
No  __  
Yes __  
No action __  
Action:   
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ID Code #_______                                                             Interview Date ________ Staff ID____ 
40. Radiation______________________________________________ Date ________ 
41. Did you develop any complications related to your treatments?  
           Complication:                         Date:              Treatment for Complication       
 ____________                  _____________________ ________  
42. What other health problems do you have? ______________________________  
43. Have you had lymphedema before the breast cancer?  
No __  
Yes __  
If yes, please describe.  
44. Has anyone in your family ever had lymphedema?  
No __  
Yes __ If yes, please describe.____________________________________________ 
45. Do you assist others with their daily care?  
No __  
Yes __  
 If yes, please describe. ___________________________________________________ 
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ID Code #_______                                                             Interview Date ________ Staff ID____ 
** Have you experienced swelling in the arm, hand, shoulder or upper body on the side where 
your cancer was first treated, or have you been diagnosed with lymphedema?  
Yes__   No__    If YES, please answer questions 46-56. If NO, please go to question 57  




How has lymphedema changed your... Now                                    
If yes, please describe.  
During Past Year                 
If yes, please describe.  
**46. Mood?  No  __  
Yes __  
No  __  
Yes __  
**47. Lifestyle?  No  __  
Yes __  
No  __  
Yes __  
**48. Time?  No  __  
Yes __  
No  __  
Yes __  
**49. Finances?  No  __  
Yes __  
No  __  
Yes __  
**50. Body image?  No  __  
Yes __  
No  __  
Yes __  
**51. Relationship to primary care 
physician?  
No  __  
Yes __  
No  __  
Yes __  
**52. Relationship to specialists?  No  __  
Yes __  
No  __  
Yes __  
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ID Code #_______                                                             Interview Date ________ Staff ID____ 
 
**53. Do you believe your doctor has been interested in treatment for your lymphedema?  
**54. Have you received helpful information for understanding and treating lymphedema?  
**55. What do you think caused your lymphedema?  
**56. What do you think makes it worse?  
   57. Do others assist you with your daily care?  
No  __  
Yes __  
If yes, please describe  
1. If you have comments you would like to make about breast cancer and lymphedema, 






                                                         













Which treatment intervention did you prefer, and why? 
                                             Manual Lymphatic Drainage (MLD) ____ 
 
                                                   Aqua Lymphatique Therapy (ALT) ____ 
 
                                             Casley-Smith exercise routine (CSER) ____ 
____________________________________________________________________________
____________________________________________________________________________ 





                                                                 CSER ____ 











Patient ID:______________            Appendix D                                    Date:____________ 





Are you experiencing:  
Time: 
                              
Time: 
                              
Time: 
                      
Time: 
                      
Time: 
12.Arm or hand 
weakness?  
No    __  
Yes   __  
No    __  
Yes   __  
No    __  
Yes   __  
No    __  
Yes   __  
No    __  
Yes   __  
16. Tenderness?  No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
17. Swelling?  No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
18. Swelling with pitting*? No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
19. Redness?  No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
20. Blistering?  No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
21. Firmness/tightness?  No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
22. Increased temperature 
in your arm? 
No    __  No    __  No    __  No    __  No    __  
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*Pitting:  when you press firmly on your skin and the dent stays long enough to feel it when you 








Yes   __  Yes   __  Yes   __  Yes   __  Yes   __  
23. Heaviness?  No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
24. Numbness?  No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
25. Stiffness?  No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
26. Aching?  No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  
Yes   __ 
No    __  





Quantitative Analysis of the abridged Lymphedema Breast Cancer Questionnaire (LBCQ) 
r × c Contingency Table: Results:  
The results of a contingency table X2 statistical test  
data: contingency table 
  A      B      C 
1      7      9      7     23 
2      7      6      5     18 
3      7     13      9     29 
4      3      5      5     13 
5      7     10     11     28 
6     24     20     18     62 
7      7     11      6     24 
8      9      7      3     19 
9     10      8      8     26 
    81     89     72    242 
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expected: contingency table 
 
        A          B          C 
 
1    7.70       8.46       6.84     
2    6.02       6.62       5.36     
3    9.71       10.7       8.63     
4    4.35       4.78       3.87     
5    9.37       10.3       8.33     
6    20.8       22.8       18.4     
7    8.03       8.83       7.14     
8    6.36       6.99       5.65     
9    8.70       9.56       7.74     
 
chi-square = 8.36  
degrees of freedom = 16 








Page/Date/Time 1    3/9/2013 10:37:00 PM 
Database D:\DOCUMENTS\CING SOUTH_FILE ... \DATA\MY DATA\3TREAT%ANNE.S0 
Response ECF_ALT 
 
Analysis of Variance Table 
Source  Sum of Mean  Prob Power 
Term DF Squares Square F-Ratio Level (Alpha=0.05) 
A: PATIENT 17 325.0898 19.12293 2.61 0.005203*  
B: Time 3 113.3017 37.76723 5.16 0.003772* 0.900113 
S 45 329.5029 7.322288 
Total (Adjusted) 65 772.1014 
Total 66 
* Term significant at alpha = 0.05 
 
Means and Standard Error Section 
   Standard 
Term Count Mean Error 
All 66 -1.472813  
A: PATIENT 
1 4 -2.45 1.352986 
2 4 -0.05 1.352986 
3 1 -1.472813 2.705973 
4 4 -0.9325 1.352986 
5 4 -0.305 1.352986 
7 4 0.7025 1.352986 
8 1 -1.472813 2.705973 
9 4 -5.3825 1.352986 
10 4 -2.0825 1.352986 
11 4 -2.16 1.352986 
12 4 0.215 1.352986 
13 4 4.5775 1.352986 
14 4 -5.0575 1.352986 
15 4 -1.36 1.352986 
16 4 -1.66 1.352986 
17 4 -2.605 1.352986 
18 4 -2.5 1.352986 
19 4 -2.515 1.352986 
B: Time 
0 18 -6.661338E-16 0.6378039 
10 16 -0.429375 0.6764932 
60 16 -2.1575 0.6764932 
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Bonferroni (All-Pairwise) Multiple Comparison Test 
 
Response: ECF_ALT 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=45  MSE=7.322288 Critical Value=2.7599 
 
   Different From 
Group Count Mean Groups 
1200 16 -3.304375 10, 0 
60 16 -2.1575  
10 16 -0.429375 1200 
0 18 -6.661338E-16 1200 
 
Notes:  
This section presents the results of all paired comparisons among the means. 
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Dunnett's Two-Sided Multiple-Comparison Test With Control 
 
Response: ECF_ALT 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=45  MSE=7.322288 Critical Value=2.4061 
 
If Control   Different From 
Group Is Count Mean Treatment Groups 
1200 16 -3.304375 10, 0 
60 16 -2.1575  
10 16 -0.429375 1200 
0 18 -6.661338E-16 1200 
 
Notes:  
This section presents the results of two-sided comparisons of each group versus the control. 
Only those groups that were different from the control group are listed. 
Since the actual control group is not specified, a separate line is generated assuming 




Duncan's Multiple-Comparison Test 
 
Response: ECF_ALT 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=45  MSE=7.322288 
 
   Different From 
Group Count Mean Groups 
1200 16 -3.304375 10, 0 
60 16 -2.1575  
10 16 -0.429375 1200 
0 18 -6.661338E-16 1200 
 
Notes:  
This report provides multiple comparison tests for all pairwise differences between 
the means. According to Hsu(1996, page 130), the specified family-wise error rate (alpha)  
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Tukey-Kramer Multiple-Comparison Test 
 
Response: ECF_ALT 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=45  MSE=7.322288 Critical Value=3.7727 
 
   Different From 
Group Count Mean Groups 
1200 16 -3.304375 10, 0 
60 16 -2.1575  
10 16 -0.429375 1200 
0 18 -6.661338E-16 1200 
 
Notes:  





Tukey-Kramer's Simultaneous Confidence Intervals for Multiple Comparisons of All Pairs 
 
Response: ECF_ALT 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=45  MSE=7.322288 Critical Value=3.7727 
 
Comparison   Lower 95.0% Mean Upper 95.0% Test 
Groups Count Mean Simult.C.I. Difference Simult.C.I. Result 
0 18 -6.661338E-16 
 - 10 16 -0.429375 -2.05093 0.429375 2.90968  
 - 60 16 -2.1575 -0.3228046 2.1575 4.637805  
 - 1200 16 -3.304375 0.8240704 3.304375 5.784679 U 
 
10 16 -0.429375 
 - 0 18 -6.661338E-16 -2.90968 -0.429375 2.05093  
 - 60 16 -2.1575 -0.8240874 1.728125 4.280337  
 - 1200 16 -3.304375 0.3227876 2.875 5.427212 U 
 
60 16 -2.1575 
 - 0 18 -6.661338E-16 -4.637805 -2.1575 0.3228046  
 - 10 16 -0.429375 -4.280337 -1.728125 0.8240874  
 - 1200 16 -3.304375 -1.405337 1.146875 3.699087  
 
1200 16 -3.304375 
 - 0 18 -6.661338E-16 -5.784679 -3.304375 -0.8240704 L 
 - 10 16 -0.429375 -5.427212 -2.875 -0.3227876 L 
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Tukey-Kramer's Simultaneous Confidence Intervals for Multiple Comparisons of All Pairs 
 
Response: ECF_ALT 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=45  MSE=7.322288 Critical Value=3.7727 
 
Comparison   Lower 95.0% Mean Upper 95.0% Test 
Groups Count Mean Simult.C.I. Difference Simult.C.I. Result 
 - 60 16 -2.1575 -3.699087 -1.146875 1.405337  
 
Notes:  
This report provides joint simultaneous confidence intervals for all pairwise differences between 
the means.  
 
Tukey-Kramer Multiple-Comparison Test  
Response: BIS_ALT 
Term B: Time 
Alpha=0.050 Error Term=S(AB)  DF=45  MSE=636.7239 Critical Value=3.7727 
            Different From  
Group Count Mean     Groups  
• 1200 16 856.9494      10, 0 
60 16 873.0944  
• 10 16 881.6569      1200 
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Database D:\DOCUMENTS\CING SOUTH_FILE ... \DATA\MY DATA\3TREAT%ANNE.S0 
Response ECF_MLD 
 
Analysis of Variance Table 
Source  Sum of Mean  Prob Power 
Term DF Squares Square F-Ratio Level (Alpha=0.05) 
A: PATIENT 18 149.3316 8.2962 1.11 0.371095  
B: Time 3 26.76542 8.921808 1.19 0.321709 0.300438 
S 48 358.389 7.466437 
Total (Adjusted) 69 534.7941 
Total 70 
* Term significant at alpha = 0.05 
 
Means and Standard Error Section 
   Standard 
Term Count Mean Error 
All 70 -0.3982353  
A: PATIENT 
1 4 -1.8675 1.366239 
2 4 1.4 1.366239 
3 4 1.1 1.366239 
4 4 0.6 1.366239 
5 4 -1.38 1.366239 
6 1 -0.3982353 2.732478 
7 4 0.1425 1.366239 
8 1 -0.3982353 2.732478 
9 4 -3.2 1.366239 
10 4 -0.855 1.366239 
11 4 0.0775 1.366239 
12 4 -0.0125 1.366239 
13 4 0.0725 1.366239 
14 4 1.4225 1.366239 
15 4 -0.005 1.366239 
16 4 -0.27 1.366239 
17 4 -1.09 1.366239 
18 4 1.0575 1.366239 
19 4 -3.9625 1.366239 
B: Time 
0 19 7.21645E-16 0.6268735 
10 17 -0.7594118 0.6627233 
60 17 -1.218235 0.6627233 
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Bonferroni (All-Pairwise) Multiple Comparison Test 
 
Response: ECF_MLD 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=48  MSE=7.466437 Critical Value=2.7520 
 
   Different From 
Group Count Mean Groups 
60 17 -1.218235  
10 17 -0.7594118  
0 19 7.21645E-16  
1200 17 0.3847059  
 
Notes:  
This section presents the results of all paired comparisons among the means. 
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Dunnett's Two-Sided Multiple-Comparison Test With Control 
 
Response: ECF_MLD 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=48  MSE=7.466437 Critical Value=2.4026 
 
If Control   Different From 
Group Is Count Mean Treatment Groups 
60 17 -1.218235  
10 17 -0.7594118  
0 19 7.21645E-16  
1200 17 0.3847059  
 
Notes:  
This section presents the results of two-sided comparisons of each group versus the control. 
Only those groups that were different from the control group are listed. 
Since the actual control group is not specified, a separate line is generated assuming 




Duncan's Multiple-Comparison Test 
 
Response: ECF_MLD 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=48  MSE=7.466437 
 
   Different From 
Group Count Mean Groups 
60 17 -1.218235  
10 17 -0.7594118  
0 19 7.21645E-16  
1200 17 0.3847059  
 
Notes:  
This report provides multiple comparison tests for all pairwise differences between 
the means. According to Hsu(1996, page 130), the specified family-wise error rate (alpha)  
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Tukey-Kramer Multiple-Comparison Test 
 
Response: ECF_MLD 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=48  MSE=7.466437 Critical Value=3.7638 
 
   Different From 
Group Count Mean Groups 
60 17 -1.218235  
10 17 -0.7594118  
0 19 7.21645E-16  
1200 17 0.3847059  
 
Notes:  





Tukey-Kramer's Simultaneous Confidence Intervals for Multiple Comparisons of All Pairs 
 
Response: ECF_MLD 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=48  MSE=7.466437 Critical Value=3.7638 
 
Comparison   Lower 95.0% Mean Upper 95.0% Test 
Groups Count Mean Simult.C.I. Difference Simult.C.I. Result 
0 19 7.21645E-16 
 - 10 17 -0.7594118 -1.668394 0.7594118 3.187217  
 - 60 17 -1.218235 -1.20957 1.218235 3.646041  
 - 1200 17 0.3847059 -2.812511 -0.3847059 2.0431  
 
10 17 -0.7594118 
 - 0 19 7.21645E-16 -3.187217 -0.7594118 1.668394  
 - 60 17 -1.218235 -2.03551 0.4588235 2.953156  
 - 1200 17 0.3847059 -3.638451 -1.144118 1.350215  
 
60 17 -1.218235 
 - 0 19 7.21645E-16 -3.646041 -1.218235 1.20957  
 - 10 17 -0.7594118 -2.953156 -0.4588235 2.03551  
 - 1200 17 0.3847059 -4.097274 -1.602941 0.8913918  
 
1200 17 0.3847059 
 - 0 19 7.21645E-16 -2.0431 0.3847059 2.812511  
 - 10 17 -0.7594118 -1.350215 1.144118 3.638451  
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Tukey-Kramer's Simultaneous Confidence Intervals for Multiple Comparisons of All Pairs 
 
Response: ECF_MLD 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=48  MSE=7.466437 Critical Value=3.7638 
 
Comparison   Lower 95.0% Mean Upper 95.0% Test 
Groups Count Mean Simult.C.I. Difference Simult.C.I. Result 
 - 60 17 -1.218235 -0.8913918 1.602941 4.097274  
 
Notes:  
This report provides joint simultaneous confidence intervals for all pairwise differences between 
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Database D:\DOCUMENTS\CING SOUTH_FILE ... \DATA\MY DATA\3TREAT%ANNE.S0 
Response ECF_CSER 
 
Analysis of Variance Table 
Source  Sum of Mean  Prob Power 
Term DF Squares Square F-Ratio Level (Alpha=0.05) 
A: PATIENT 18 197.9137 10.99521 1.63 0.088200  
B: Time 3 23.37518 7.791728 1.15 0.336800 0.291944 
S 51 344.6609 6.758056 
Total (Adjusted) 72 566.3669 
Total 73 
* Term significant at alpha = 0.05 
 
Means and Standard Error Section 
   Standard 
Term Count Mean Error 
All 73 -0.6502778  
A: PATIENT 
1 4 -0.4275 1.299813 
2 4 -1.4325 1.299813 
3 1 -0.6502778 2.599626 
4 4 -3.0475 1.299813 
5 4 -1.8025 1.299813 
6 4 0.94 1.299813 
7 4 -4.225 1.299813 
8 4 1.415 1.299813 
9 4 1.035 1.299813 
10 4 -0.6875 1.299813 
11 4 -1.37 1.299813 
12 4 2.2375 1.299813 
13 4 0.475 1.299813 
14 4 -0.5925 1.299813 
15 4 0.525 1.299813 
16 4 -1.17 1.299813 
17 4 -0.9375 1.299813 
18 4 -3.1325 1.299813 
19 4 0.4925 1.299813 
B: Time 
0 19 -1.110223E-16 0.5963951 
10 18 -1.387778 0.6127378 
60 18 -1.011667 0.6127378 
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Bonferroni (All-Pairwise) Multiple Comparison Test 
 
Response: ECF_CSER 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=51  MSE=6.758056 Critical Value=2.7451 
 
   Different From 
Group Count Mean Groups 
10 18 -1.387778  
60 18 -1.011667  
1200 18 -0.2016667  
0 19 -1.110223E-16  
 
Notes:  
This section presents the results of all paired comparisons among the means. 
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Dunnett's Two-Sided Multiple-Comparison Test With Control 
 
Response: ECF_CSER 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=51  MSE=6.758056 Critical Value=2.4011 
 
If Control   Different From 
Group Is Count Mean Treatment Groups 
10 18 -1.387778  
60 18 -1.011667  
1200 18 -0.2016667  
0 19 -1.110223E-16  
 
Notes:  
This section presents the results of two-sided comparisons of each group versus the control. 
Only those groups that were different from the control group are listed. 
Since the actual control group is not specified, a separate line is generated assuming 




Duncan's Multiple-Comparison Test 
 
Response: ECF_CSER 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=51  MSE=6.758056 
 
   Different From 
Group Count Mean Groups 
10 18 -1.387778  
60 18 -1.011667  
1200 18 -0.2016667  
0 19 -1.110223E-16  
 
Notes:  
This report provides multiple comparison tests for all pairwise differences between 
the means. According to Hsu(1996, page 130), the specified family-wise error rate (alpha)  
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Tukey-Kramer Multiple-Comparison Test 
 
Response: ECF_CSER 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=51  MSE=6.758056 Critical Value=3.7559 
 
   Different From 
Group Count Mean Groups 
10 18 -1.387778  
60 18 -1.011667  
1200 18 -0.2016667  
0 19 -1.110223E-16  
 
Notes:  





Tukey-Kramer's Simultaneous Confidence Intervals for Multiple Comparisons of All Pairs 
 
Response: ECF_CSER 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=51  MSE=6.758056 Critical Value=3.7559 
 
Comparison   Lower 95.0% Mean Upper 95.0% Test 
Groups Count Mean Simult.C.I. Difference Simult.C.I. Result 
0 19 -1.110223E-16 
 - 10 18 -1.387778 -0.8831159 1.387778 3.658671  
 - 60 18 -1.011667 -1.259227 1.011667 3.28256  
 - 1200 18 -0.2016667 -2.069227 0.2016667 2.47256  
 
10 18 -1.387778 
 - 0 19 -1.110223E-16 -3.658671 -1.387778 0.8831159  
 - 60 18 -1.011667 -2.677488 -0.3761111 1.925266  
 - 1200 18 -0.2016667 -3.487488 -1.186111 1.115266  
 
60 18 -1.011667 
 - 0 19 -1.110223E-16 -3.28256 -1.011667 1.259227  
 - 10 18 -1.387778 -1.925266 0.3761111 2.677488  
 - 1200 18 -0.2016667 -3.111377 -0.81 1.491377  
 
1200 18 -0.2016667 
 - 0 19 -1.110223E-16 -2.47256 -0.2016667 2.069227  
 - 10 18 -1.387778 -1.115266 1.186111 3.487488  
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Tukey-Kramer's Simultaneous Confidence Intervals for Multiple Comparisons of All Pairs 
 
Response: ECF_CSER 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=51  MSE=6.758056 Critical Value=3.7559 
 
Comparison   Lower 95.0% Mean Upper 95.0% Test 
Groups Count Mean Simult.C.I. Difference Simult.C.I. Result 
 - 60 18 -1.011667 -1.491377 0.81 3.111377  
 
Notes:  
This report provides joint simultaneous confidence intervals for all pairwise differences between 
















Page/Date/Time 1    3/10/2013 11:09:31 AM 
Database D:\DOCUMENTS\CING SOUTH_FILE ... \DATA\MY DATA\3TREAT%ANNE.S0 
Response CM_ALT 
 
Analysis of Variance Table 
Source  Sum of Mean  Prob Power 
Term DF Squares Square F-Ratio Level (Alpha=0.05) 
A: PATIENT 18 169.0128 9.389601 2.52 0.006147*  
B: Time 3 19.14537 6.381789 1.71 0.177638 0.417665 
S 45 167.567 3.72371 
Total (Adjusted) 66 355.9085 
Total 67 
* Term significant at alpha = 0.05 
 
Means and Standard Error Section 
   Standard 
Term Count Mean Error 
All 67 -0.2529688  
A: PATIENT 
1 4 -1.825 0.9648458 
2 4 1.8925 0.9648458 
3 1 -0.2529688 1.929692 
4 4 -0.1175 0.9648458 
5 4 -1.92 0.9648458 
6 1 -0.2529688 1.929692 
7 4 -1.7725 0.9648458 
8 1 -0.2529688 1.929692 
9 4 -0.9 0.9648458 
10 4 1.04 0.9648458 
11 4 1.345 0.9648458 
12 4 -1.46 0.9648458 
13 4 0.035 0.9648458 
14 4 -1.5325 0.9648458 
15 4 1.3275 0.9648458 
16 4 -0.65 0.9648458 
17 4 1.9875 0.9648458 
18 4 1.905 0.9648458 
19 4 -3.4025 0.9648458 
B: Time 
0 19 7.771561E-16 0.4427016 
10 16 -0.035625 0.4824229 
60 16 -1.18625 0.4824229 
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Bonferroni (All-Pairwise) Multiple Comparison Test 
 
Response: CM_ALT 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=45  MSE=3.72371 Critical Value=2.7599 
 
   Different From 
Group Count Mean Groups 
60 16 -1.18625  
10 16 -0.035625  
0 19 7.771561E-16  
1200 16 0.21  
 
Notes:  
This section presents the results of all paired comparisons among the means. 
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Dunnett's Two-Sided Multiple-Comparison Test With Control 
 
Response: CM_ALT 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=45  MSE=3.72371 Critical Value=2.4043 
 
If Control   Different From 
Group Is Count Mean Treatment Groups 
60 16 -1.18625  
10 16 -0.035625  
0 19 7.771561E-16  
1200 16 0.21  
 
Notes:  
This section presents the results of two-sided comparisons of each group versus the control. 
Only those groups that were different from the control group are listed. 
Since the actual control group is not specified, a separate line is generated assuming 




Duncan's Multiple-Comparison Test 
 
Response: CM_ALT 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=45  MSE=3.72371 
 
   Different From 
Group Count Mean Groups 
60 16 -1.18625  
10 16 -0.035625  
0 19 7.771561E-16  
1200 16 0.21  
 
Notes:  
This report provides multiple comparison tests for all pairwise differences between 
the means. According to Hsu(1996, page 130), the specified family-wise error rate (alpha)  
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Tukey-Kramer Multiple-Comparison Test 
 
Response: CM_ALT 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=45  MSE=3.72371 Critical Value=3.7727 
 
   Different From 
Group Count Mean Groups 
60 16 -1.18625  
10 16 -0.035625  
0 19 7.771561E-16  
1200 16 0.21  
 
Notes:  





Tukey-Kramer's Simultaneous Confidence Intervals for Multiple Comparisons of All Pairs 
 
Response: CM_ALT 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=45  MSE=3.72371 Critical Value=3.7727 
 
Comparison   Lower 95.0% Mean Upper 95.0% Test 
Groups Count Mean Simult.C.I. Difference Simult.C.I. Result 
0 19 7.771561E-16 
 - 10 16 -0.035625 -1.711096 0.035625 1.782346  
 - 60 16 -1.18625 -0.5604711 1.18625 2.932971  
 - 1200 16 0.21 -1.956721 -0.21 1.536721  
 
10 16 -0.035625 
 - 0 19 7.771561E-16 -1.782346 -0.035625 1.711096  
 - 60 16 -1.18625 -0.6694168 1.150625 2.970667  
 - 1200 16 0.21 -2.065667 -0.245625 1.574417  
 
60 16 -1.18625 
 - 0 19 7.771561E-16 -2.932971 -1.18625 0.5604711  
 - 10 16 -0.035625 -2.970667 -1.150625 0.6694168  
 - 1200 16 0.21 -3.216292 -1.39625 0.4237918  
 
1200 16 0.21 
 - 0 19 7.771561E-16 -1.536721 0.21 1.956721  
 - 10 16 -0.035625 -1.574417 0.245625 2.065667  
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Tukey-Kramer's Simultaneous Confidence Intervals for Multiple Comparisons of All Pairs 
 
Response: CM_ALT 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=45  MSE=3.72371 Critical Value=3.7727 
 
Comparison   Lower 95.0% Mean Upper 95.0% Test 
Groups Count Mean Simult.C.I. Difference Simult.C.I. Result 
 - 60 16 -1.18625 -0.4237918 1.39625 3.216292  
 
Notes:  
This report provides joint simultaneous confidence intervals for all pairwise differences between 
















Page/Date/Time 1    3/10/2013 11:11:08 AM 
Database D:\DOCUMENTS\CING SOUTH_FILE ... \DATA\MY DATA\3TREAT%ANNE.S0 
Response CM_MLD 
 
Analysis of Variance Table 
Source  Sum of Mean  Prob Power 
Term DF Squares Square F-Ratio Level (Alpha=0.05) 
A: PATIENT 18 93.11005 5.172781 2.07 0.023146*  
B: Time 3 11.09998 3.699994 1.48 0.231704 0.366594 
S 48 119.9701 2.499378 
Total (Adjusted) 69 224.2076 
Total 70 
* Term significant at alpha = 0.05 
 
Means and Standard Error Section 
   Standard 
Term Count Mean Error 
All 70 0.1186765  
A: PATIENT 
1 4 0.415 0.7904711 
2 4 -1.23 0.7904711 
3 4 -0.0275 0.7904711 
4 4 -0.3725 0.7904711 
5 4 -0.8975 0.7904711 
6 1 0.1186765 1.580942 
7 4 -1.6025 0.7904711 
8 1 0.1186765 1.580942 
9 4 0.335 0.7904711 
10 4 -0.6725 0.7904711 
11 4 -0.05 0.7904711 
12 4 0.02 0.7904711 
13 4 3.59 0.7904711 
14 4 -0.1975 0.7904711 
15 4 2.15 0.7904711 
16 4 -0.0025 0.7904711 
17 4 0.13 0.7904711 
18 4 0.43 0.7904711 
19 4 7.21645E-16 0.7904711 
B: Time 
0 19 -6.106227E-16 0.362693 
10 17 -0.3252941 0.3834348 
60 17 2.352941E-02 0.3834348 
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Bonferroni (All-Pairwise) Multiple Comparison Test 
 
Response: CM_MLD 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=48  MSE=2.499378 Critical Value=2.7520 
 
   Different From 
Group Count Mean Groups 
10 17 -0.3252941  
0 19 -6.106227E-16  
60 17 2.352941E-02  
1200 17 0.7764706  
 
Notes:  
This section presents the results of all paired comparisons among the means. 
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Dunnett's Two-Sided Multiple-Comparison Test With Control 
 
Response: CM_MLD 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=48  MSE=2.499378 Critical Value=2.4026 
 
If Control   Different From 
Group Is Count Mean Treatment Groups 
10 17 -0.3252941  
0 19 -6.106227E-16  
60 17 2.352941E-02  
1200 17 0.7764706  
 
Notes:  
This section presents the results of two-sided comparisons of each group versus the control. 
Only those groups that were different from the control group are listed. 
Since the actual control group is not specified, a separate line is generated assuming 




Duncan's Multiple-Comparison Test 
 
Response: CM_MLD 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=48  MSE=2.499378 
 
   Different From 
Group Count Mean Groups 
10 17 -0.3252941  
0 19 -6.106227E-16  
60 17 2.352941E-02  
1200 17 0.7764706  
 
Notes:  
This report provides multiple comparison tests for all pairwise differences between 
the means. According to Hsu(1996, page 130), the specified family-wise error rate (alpha)  
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Tukey-Kramer Multiple-Comparison Test 
 
Response: CM_MLD 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=48  MSE=2.499378 Critical Value=3.7638 
 
   Different From 
Group Count Mean Groups 
10 17 -0.3252941  
0 19 -6.106227E-16  
60 17 2.352941E-02  
1200 17 0.7764706  
 
Notes:  





Tukey-Kramer's Simultaneous Confidence Intervals for Multiple Comparisons of All Pairs 
 
Response: CM_MLD 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=48  MSE=2.499378 Critical Value=3.7638 
 
Comparison   Lower 95.0% Mean Upper 95.0% Test 
Groups Count Mean Simult.C.I. Difference Simult.C.I. Result 
0 19 -6.106227E-16 
 - 10 17 -0.3252941 -1.079372 0.3252941 1.72996  
 - 60 17 2.352941E-02 -1.428196 -2.352941E-02 1.381137  
 - 1200 17 0.7764706 -2.181137 -0.7764706 0.6281957  
 
10 17 -0.3252941 
 - 0 19 -6.106227E-16 -1.72996 -0.3252941 1.079372  
 - 60 17 2.352941E-02 -1.791981 -0.3488235 1.094334  
 - 1200 17 0.7764706 -2.544922 -1.101765 0.3413927  
 
60 17 2.352941E-02 
 - 0 19 -6.106227E-16 -1.381137 2.352941E-02 1.428196  
 - 10 17 -0.3252941 -1.094334 0.3488235 1.791981  
 - 1200 17 0.7764706 -2.196099 -0.7529412 0.6902162  
 
1200 17 0.7764706 
 - 0 19 -6.106227E-16 -0.6281957 0.7764706 2.181137  
 - 10 17 -0.3252941 -0.3413927 1.101765 2.544922  
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Tukey-Kramer's Simultaneous Confidence Intervals for Multiple Comparisons of All Pairs 
 
Response: CM_MLD 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=48  MSE=2.499378 Critical Value=3.7638 
 
Comparison   Lower 95.0% Mean Upper 95.0% Test 
Groups Count Mean Simult.C.I. Difference Simult.C.I. Result 
 - 60 17 2.352941E-02 -0.6902162 0.7529412 2.196099  
 
Notes:  
This report provides joint simultaneous confidence intervals for all pairwise differences between 
















Page/Date/Time 1    3/10/2013 11:12:12 AM 
Database D:\DOCUMENTS\CING SOUTH_FILE ... \DATA\MY DATA\3TREAT%ANNE.S0 
Response CM_CSER 
 
Analysis of Variance Table 
Source  Sum of Mean  Prob Power 
Term DF Squares Square F-Ratio Level (Alpha=0.05) 
A: PATIENT 18 185.1591 10.28662 3.31 0.000407*  
B: Time 3 3.3159 1.1053 0.36 0.785494 0.114832 
S 51 158.6568 3.110918 
Total (Adjusted) 72 347.2608 
Total 73 
* Term significant at alpha = 0.05 
 
Means and Standard Error Section 
   Standard 
Term Count Mean Error 
All 73 0.3616667  
A: PATIENT 
1 4 0.6175 0.8818897 
2 4 -0.28 0.8818897 
3 1 0.3616667 1.763779 
4 4 1.2475 0.8818897 
5 4 -3.7775 0.8818897 
6 4 -0.1625 0.8818897 
7 4 3.31 0.8818897 
8 4 1.0525 0.8818897 
9 4 2.1 0.8818897 
10 4 0.8875 0.8818897 
11 4 -1.5675 0.8818897 
12 4 0.4 0.8818897 
13 4 1.7675 0.8818897 
14 4 -0.9575 0.8818897 
15 4 2.4675 0.8818897 
16 4 0.77 0.8818897 
17 4 -1.1525 0.8818897 
18 4 0.33 0.8818897 
19 4 -0.5425 0.8818897 
B: Time 
0 19 0 0.4046387 
10 18 0.4066667 0.4157268 
60 18 0.495 0.4157268 
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Bonferroni (All-Pairwise) Multiple Comparison Test 
 
Response: CM_CSER 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=51  MSE=3.110918 Critical Value=2.7451 
 
   Different From 
Group Count Mean Groups 
0 19 0  
10 18 0.4066667  
60 18 0.495  
1200 18 0.545  
 
Notes:  
This section presents the results of all paired comparisons among the means. 
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Dunnett's Two-Sided Multiple-Comparison Test With Control 
 
Response: CM_CSER 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=51  MSE=3.110918 Critical Value=2.4011 
 
If Control   Different From 
Group Is Count Mean Treatment Groups 
0 19 0  
10 18 0.4066667  
60 18 0.495  
1200 18 0.545  
 
Notes:  
This section presents the results of two-sided comparisons of each group versus the control. 
Only those groups that were different from the control group are listed. 
Since the actual control group is not specified, a separate line is generated assuming 




Duncan's Multiple-Comparison Test 
 
Response: CM_CSER 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=51  MSE=3.110918 
 
   Different From 
Group Count Mean Groups 
0 19 0  
10 18 0.4066667  
60 18 0.495  
1200 18 0.545  
 
Notes:  
This report provides multiple comparison tests for all pairwise differences between 
the means. According to Hsu(1996, page 130), the specified family-wise error rate (alpha)  
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Tukey-Kramer Multiple-Comparison Test 
 
Response: CM_CSER 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=51  MSE=3.110918 Critical Value=3.7559 
 
   Different From 
Group Count Mean Groups 
0 19 0  
10 18 0.4066667  
60 18 0.495  
1200 18 0.545  
 
Notes:  




             Tukey-Kramer's Simultaneous Confidence Intervals for Multiple Comparisons of All Pairs 
 
Response: CM_CSER 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=51  MSE=3.110918 Critical Value=3.7559 
 
Comparison   Lower 95.0% Mean Upper 95.0% Test 
Groups Count Mean Simult.C.I. Difference Simult.C.I. Result 
0 19 0 
 - 10 18 0.4066667 -1.94741 -0.4066667 1.134076  
 - 60 18 0.495 -2.035743 -0.495 1.045743  
 - 1200 18 0.545 -2.085743 -0.545 0.9957429  
 
10 18 0.4066667 
 - 0 19 0 -1.134076 0.4066667 1.94741  
 - 60 18 0.495 -1.649758 -8.833333E-02 1.473092  
 - 1200 18 0.545 -1.699758 -0.1383333 1.423092  
 
60 18 0.495 
 - 0 19 0 -1.045743 0.495 2.035743  
 - 10 18 0.4066667 -1.473092 8.833333E-02 1.649758  
 - 1200 18 0.545 -1.611425 -0.05 1.511425  
 
1200 18 0.545 
 - 0 19 0 -0.9957429 0.545 2.085743  
 - 10 18 0.4066667 -1.423092 0.1383333 1.699758  
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Tukey-Kramer's Simultaneous Confidence Intervals for Multiple Comparisons of All Pairs 
 
Response: CM_CSER 
Term B: Time 
 
Alpha=0.050  Error Term=S(AB)  DF=51  MSE=3.110918 Critical Value=3.7559 
 
Comparison   Lower 95.0% Mean Upper 95.0% Test 
Groups Count Mean Simult.C.I. Difference Simult.C.I. Result 
 - 60 18 0.495 -1.511425 0.05 1.611425  
 
Notes:  
This report provides joint simultaneous confidence intervals for all pairwise differences between 
the means.  
 
 
 
 
